

SARS.CAUSEOF DEATH.V

SARS-CoV-2-Infection (COVID-19): Clinical Course and CAUSE (S) OF DEATH

Giuliano Ramadori M D Professor of Medicine, Göttingen, Germany

Address for correspondence:

gramado@med.uni-goettingen.de

giulianoramadori@gmail.com

**key words: SARS-CoV-2-
infection,dehydration,hypoalbuminemia,pulmonary
hypoxia,hyaline membrane,pulmonary engorgement,lung weight
,acute respiratory distress syndrome,(),diffuse alveolar damage
(DAD)**

ABSTRACT

Two years after first patients approached the emergency rooms of hospitals in Wuhan because of respiratory distress, thousand of SARS-CoV-2 infected persons continue to die every day worldwide. SARS-CoV-2-infected patients undergo a process of dehydration and malnutrition before they develop respiratory problems and approach the emergency room of a hospital. This is, in many cases, the consequence of high fever which causes massive loss of fluids. In addition loss of appetite, is responsible for the deficit of protein intake. Most of the virus-infected patients admitted to the emergency room are therefore hypovolemic and hypoproteinemic and suffer of respiratory distress accompanied by ground glass opacities at CT-scan of the lungs. Critically ill patients are treated following the guidelines for treatment of septic shock but with „conservative“ fluid replacement and administration of diuretics to assure sufficient hourly urine production.

The combination of conservative fluid administration with reduced protein content in the enterally administered diet, together with administration of diuretics, has severe hemodynamic consequences in mostly aged, dehydrated, critically ill patients. Many of them will develop acute kidney injury in the next 24 hours.

In most of the cases, patients continue to loose weight by losing skeletal muscle mass.

Ischemic damage in the lung capillaries is responsible for the acute respiratory distress syndrome (ARDS) and for the hallmark of autptic findings, diffuse alveolar damage (DAD) characterized by hyaline membrane formation, fluid invasion of the alveoli recruitment of some inflammatory cells and progressive arrest of blood flow in the pulmonary vessels. The consequence is progressive congestion, increase of lung weight and progressive hypoxia (progressive severity of ARDS). Sequestration of blood in the lungs worsen hypovolemia and ischemia in different organs. This is most probably responsible for recruitment of inflammatory cells and for persistence of elevated serum levels of positive acute-phase markers and of hypoalbuminemia.

Autoptic studies have been performed mostly in patients who died in the ICU after SARS-CoV-2-infection because of progressive ARDS. In those patients, tubulus epithelium necrosis in the kidney is a frequent finding as it has been the case in the first SARS-CoV-1 pandemic. In the death certification charts, many times weeks after first symptoms have started, cardiac arrest is the cause of death after respiratory insufficiency.

Replacement therapy with sufficient amount of fluid and albumin should be part of the early individualized life-saving supportive measures avoiding mechanical ventilation.

Key words: COVID-19, autopsy, lung, bronchial epithelium, nasal mucosa, albumin infusion, tissue ischemia, dehydration, liquid and nutrition, cardiac arrest, cause of death.

SARS-CoV-2-infection (COVID-19): Clinical Course and CAUSE (S) OF DEATH

Ramadori Giuliano MD

More than two years after the beginning of the pandemic, more than 470 million people have contracted the HCoV-2 infection and more than 6 million people have died(1).The true number of death could be however much higher (2,3)

While the age of the patients hospitalized in Wuhan was mostly under 65 years, (4-8) the first children of a mean of 3 years of age were observed from january 7 to january 15,2020(9) with an ICU admission. Nine more cases observed in january/february 2020 were described (10). Children continue to be infected and eventually die also in the western countries (11,12).

As in most of non- hospitalized cases but also in hospitalized persons who die of HuCoV-2 infection, the cause of death is respiratory insufficiency (ARDS) with the classical CT-scan finding of the chest of the so called ground glass opacities (GGO), supposed to be due to directly induced viral damage, it is important to reconstruct the chronologic sequence of clinical events and of the changes detected by radiological imaging and to correlate them with the available autptic findings published until recently.

Most of the reports are based on data obtained on hospitalisation whereas data collected at the beginning of the symptoms and during the prehospitalisation time are scarce.

Treatment guidelines therefore mostly concern the antiviral treatment and the suppression of the acute-phase reaction with experimental drugs, starting at the beginning of the hospitalization before entering and/or during the ICU-stay (13-15) which have been previously studied in therapeutic trials under different protection conditions for the health care professionals .

Compared to the high number of therapeutic trials performed on hospitalized patients , much less attention has been paid to the treatment of the initial symptoms in order to prevent physical deterioration and the need of hospitalisation(16-22).

The clinical course of HuCoV-2- and of Influenza-infection is quite similar(23-28):runny or stuffy nose,headache,dry cough sore throat,fatigue,muscle pain fever of different height and length,inappetence,vomiting , diarrhea which may then lead to developement of shortness of breath or difficulty of breathing.To these symptoms can be added oliguria and loss of body weight (29,30).

In many cases,because of the fear of infection transmission within the family member as soon as the oximeter shows a $pO_2 < 93\%$, help in the emergency room of an hospital is sought even without symptoms of shortness of breath or increase of breath frequency.

At this time, several days after beginning of symptoms, chest x-ray studies may, at first, result normal and CT-values of PCR-analysis may suggest low viral load.

Chest-CT-scan performed at the same time or one or two days later may show ground glass opacities in the subpleural dorsal and in basal portions of the lungs (Fig.1) suggesting a risk of progress into acute respiratory distress syndrome (ARDS).



Fig.1: Two days before admission the conventional radiology of the chest was normal and the patient was released from the emergency room. He was readmitted two days later. CT-scan of the chest in the 74 year-old COVID-19-patient showed bilateral opacities. At time of this CT-scan CRP serum level was normal. Patient was then mechanically ventilated but could be released after 8 weeks of stay at the ICU and send for rehabilitative therapy.

A further decrease of PaO₂ may lead to the decision of mechanical ventilation (31,32) with the diagnosis of ARDS often depending on setting and circumstances (33) which may also have been influenced, at least in part by the administering of experimental drugs.

The first person who officially died of COVID-19 in Italy in Vo`Euganeo on february 20th was a 78 year-old man (34). Thereafter most of the patients who died of COVID-19 in Italy were over 80 years old (35-37). The same events were observed in Germany, in Denmark, Sweden and in the other countries of the western world (38-42) where more than two thirds of the people who died of COVID-19 were old or very old, although the majority of the infected people ranged between 15-60 years of age.

This discrepancy has been explained by the special frailty of the older patients.

persons due to the presence of different comorbidities like hypertension, diabetes, chronic lung or kidney disease (43-46). Most of the old persons who were infected and died lived in assisted retirement facilities. Mortality in such houses however was dependent on the care organisation. In fact in some of them mortality could be strongly reduced or even completely avoided (47).

Although several clinical patterns have been reported, fever and dry cough are the most frequent symptoms reported as the beginning of the disease (20% of the PCR-positive persons) with further (6-9 day after beginning of first symptoms) worsening characterized by dyspnea of different degrees (5%) leading to hospitalisation (48,49) and eventually to ICU (50).

Anamnestic informations given by the patients demselves or by their relatives concerning the beginning of the symptoms,the clinical developement and the duration of the symptoms in the pre-hospitalisation time have been often unprecise.

In fact, as many old patients were brought to the hospitals from assisted care facilities it was very difficult to ask about height and duration of fever,fluid and calory uptake , changes in body weight since symptoms first appeared and which drugs were regularly administered.As the modern doctor has less and less time for contact with his patients and with their families (51,52),this may have been even more difficult during the first wave of the SARS-CoV-2-pandemic,because of the exceptional situation in the emergency room due to overcrowding and the fear of contagion by the diffuse lack of preventive measures among the health care personnel.

The physical conditions of the old infected patients,which normally require a careful examination of the skin and mucosal surfaces, hydration status examination has often been impossible and therefore not reported (51,52).

In many cases, immediately after admission, patients have been sent to the radiology department for diagnostic chest-CT-scan (53).

This, In fact, was due,at least in part, to the overcrowding of the emergency rooms, because of lack of time to wait for the virological diagnostic procedure (where available).It also led to further delay of supportive therapy (administration of fluids and nutrition (54-56).

Diagnostic pictures from this source have then dominated the further clinical proceedings,e.g.hospitalisation and eventually mechanical ventilation.

Administration of antiviral drugs and even more frequently of corticosteroids was considered a priority (8,43,54,55) as it was suggested that these would be effective if administered early(56).

Two publications (7,57) concentrated on the changes of serum levels of inflammatory cytokines,mainly Interleukin-6,TNF-alpha,Interleukin-1-beta and also interleukin-8 (58) during the hospitalisation.In the first publication a decrease of the acute-phase cytokines IL-6 and TNF-alpha was observed in the serum of patients who were discharged from the hospital.IL-1-Beta serum level was slightly elevated only in three of 27 patients studied (7).In the second publication (57) serum level of IL-6,TNF-alpha and IL-8 were significantly elevated in COVID-19-patients,IL-6 being the most prominent cytokine (all in the order of magnitude of picogram/ml).IL-1-beta-serum level was always low or at the limit of detection.

Therefore a difference in the behavior of the serum levels of these acute-phase cytokines was observed and „different cutoffs were chosen for further statistical analysis“ (57).Authors found that the serum level of the cytokines was differently associated with comorbidities.

The first determination of IL-6 and TNF-alpha-serum levels after hospitalisation was indicative for the prognosis of the patient,higher levels having a bad prognostic meaning.Especially IL-6- and IL-8-initial serum levels were closely correlated with severe disease with signs of organ failure showing disastrous lung imaging,reduction of creatinin clearance,the need for vasopressors and use of ventilation.

Under the effect of experimental drugs such as IL-6-receptor antagonists, corticosteroids or remdesivir there was a fluctuation of IL-6 serum levels with a potentially positive effect on prognosis. Changes of viral load were not reported.

The discussion about the source of the acute-phase cytokines and of their role and meaning within the clinical picture of COVID-19 focused more on the possible use of the measurement of serum levels to determine prognosis.

While the main acute-phase cytokine, IL-6 is mainly synthesized by macrophages recruited at the site of „aggression“ and tissue damage, the chemokine IL-8 is also locally synthesized by every cell under „attack“ and contributes to the local recruitment of inflammatory cells.

Increase of IL-8-serum levels under such acute-phase conditions, however, is more dependent on the magnitude of IL-6-serum level, which induces production of the chemokine in the liver (59) which has to be high enough to induce increased release of granulocytes from the bone marrow (60,61).

In fact, especially in viral diseases, like COVID-19 the serum level of IL-6 and consequently of IL-8 does not seem to be high enough to induce the massive increase of leukocyte count which is characteristic for bacterial infections or for other acute clinical situations (62-65).




Figure 7 Expression of CINC-1 mRNA (a) and protein (b) in liver and injured muscle, and mRNA of acute-phase cytokines in liver (c) and injured muscle (d) at different time points after intramuscular TO treatment. The mRNA expression was quantified by real-time RT-PCR (a, c and d). CINC-1 protein was quantified by ELISA in lysates of liver and injured muscle (b). The CINC-1 concentrations were related to the total protein of the lysates, based on total protein concentration measurements (b). CINC-1 protein was induced in liver 2 h after TO injection, while at the site of TO injection the induction occurred only 4 h after the TO injection. Results represent mean value \pm s.e.m. of three animals. * $P < 0.05$.

Fig.2: Induction of chemokine- (CINC-1, Il-8)-gene-expression(mRNA and protein) in the liver and in the muscle of TO-treated rats (a,b).Cytokine-gene-expression in the liver and in the injured muscle at different time after intramuscular TO-administration (c-d).The enormous increase of the IL-6-gene-expression in the injured muscle parallels the 300 fold- increase of Il-8-gene-expression in the liver while the increase of expression the same gene was temporarily about five fold (a)(58).




Fig.3: Induction of chemokine- (CINC-1, Il-8) -gene-expression in cultured rat hepatocytes by treatment with different amounts of Il-1-beta, Il-6 or TNF-alpha. Northern blot analysis of total RNA hybridized with the specific radioactive cDNA. The quantification of the signal in

relation to that of the house-keeping- RNA indicates that IL-6 (but also IL-1) has the highest potency of induction of IL-8 in hepatocytes(58).With permission.

A great amount of data has been generated mostly by analyzing samples from hospitalized patients (66-84) but in most of the cases, with a few exceptions, the effect of the different drugs administered immediately on admission (7,55) has not been considered.

Interestingly a previously published work from France (75) seems to confirm the laboratory changes which could be supposed from the publication of Xie (26) and coworkers.

The French authors(75) followed the laboratory changes observed in 162 patients during their hospital stay. They showed an increase of the number of patients developing acute kidney injury (AKI) from 0% on admission to 21.4% at day 14. At the same time increased osmolality and increased CRP- serum levels were observed while albumin serum level (below 25 g/L) continuously decreased.

Hyperamylasemia was also present but morphological signs of acute pancreatitis were lacking .

However, although the data strongly suggests hypovolemic pre-renal insufficiency as well explained by Sise et al (80) and by Bowe et al(81), no information has been given about the serial measurements of blood volume .

On the contrary , viral replication in organs outside the respiratory tract has been repeatedly made responsible for organ „injury“. Continuous determination of the viral presence during hospitalisation has however been rarely reported.

The work published by Xie et al.(26) shows interesting aspects which derive not only from the description of the changes observed during hospitalisation in COVID-19 patients but through the comparison with patients admitted to the hospitals because of influenza infection in the 3 years preceding the COVID-19 pandemic. Although the admission characteristics of the influenza infected (75% white and 25% black) and of those COVID-19- patients (50% white and 50% black) were quite similar, in white patients with COVID-19, mortality, although lower than in the black population, was more than three times higher than in the influenza-infected patients. This because of the worsening of the clinical conditions occurring after hospitalisation (26).

In an attempt to create the basis for personalized treatment(s), mortality risk scores have been developed, by different means retrospectively, analyzing the clinical data and laboratory parameters derived from blood and sometimes urine samples taken on admission to hospital, mostly under the conditions mentioned above (85-92).

The laboratory data collected also during the stay in hospital, which were used to extrapolate the clinical development and somehow to explain clinical processes which then ended, in part of the patients with death, measures such as transfer to ICU, use of mechanical ventilation and kidney replacement therapy were used as prognostic markers but therapeutic consequences were not discussed.

The negative prognostic value of hypoalbuminemia was repeatedly described (93) at the beginning of the pandemic. The crucial importance of normal serum albumin level has been, however, underestimated (94-98)

The increased use of diuretics, which are routinely given on the assumption that ARDS is a kind of non-cardial „edema“ of the lung, has only been reported in a recent publication (99).

Instead, use of vasopressors is quite often mentioned also in guidelines without explanation for their being necessary, even when cardiac arrhythmias can occur as a consequence without signs of cardiac damage or insufficiency (100).

Hypoxia without a cardiac cause represents *the conditio sine qua non* for the diagnosis of acute respiratory distress syndrome (ARDS) when hypoxemia occurs in COVID-19-patients showing diffuse ground-glass opacities at the CT-scan of the chest.

Compared to patients with influenza infection, patients who were diagnosed COVID-19 were found to have an increased risk of extrapulmonary organ failure associated with an increased use of „health resources“.

The main question is therefore whether this development after hospitalisation is due to viral replication or to the increased administration of drugs, which seem to aggravate in many cases preexisting conditions such as hypoalbuminemia (86,93) and dehydration (29). These are eventually the basis for hemodynamic changes leading to most of the complications with the need of routinely administered catecholamins /(vasopressors) and to death especially in older persons.

This, although Huang J et al. (93) in their retrospective analysis of the charts of 299 COVID-19 patients found that hypoalbuminemia could predict outcome independently of age and comorbidities.

As in most of non-hospitalized cases but also in hospitalized persons who die of HuCoV-2 infection, the cause of death is respiratory insufficiency (ARDS) supposed to be due to directly induced viral damage, it is important to reconstruct the chronologic sequence of clinical events and of the changes detected by radiological imaging and to correlate them with the available autopsic findings published until recently.

Most of the reports are based on data obtained on hospitalisation whereas data collected at the beginning of the symptoms and during the prehospitalisation time are scarce.

Treatment guidelines therefore mostly concerned with the antiviral treatment and the suppression of the acute-phase reaction with experimental drugs, starting at the beginning of the hospitalization before entering and/or during the ICU-stay (31-33) which have been previously studied in therapeutic trials under different protection conditions for the health care professionals.

Compared to the high number of therapeutic trials performed on hospitalized patients, much less attention has been paid to the treatment of the initial symptoms in order to prevent physical deterioration and the need of hospitalisation (16-22).

As mentioned above, the clinical course of HuCoV-2- and of Influenza-infection is quite similar (13,16,17,19,25,98,): runny or stuffy nose, headache, dry cough sore throat, fatigue, muscle pain fever of different height and length, inappetence, vomiting, diarrhea which may then lead to development of shortness of breath or difficulty of breathing. To these symptoms can be added oliguria and loss of body weight (16,27).

In many cases, because of the fear of infection transmission within the family member as soon as the oximeter shows a $pO_2 < 93\%$, help in the emergency room of an hospital is sought even without symptoms of shortness of breath or increase of breath frequency.

At this time, several days after beginning of symptoms, chest x-ray studies may, at first, result normal and CT-values of PCR-analysis may suggest low viral load.

Chest-CT-scan performed at the same time or one or two days later may show ground glass opacities in the subpleural dorsal and in basal portions of the lungs (Fig.1) suggesting a risk of progress into ARDS.

A further decrease of PaO_2 may lead to the decision of mechanical ventilation (13,14) with the diagnosis of ARDS often depending on setting and circumstances (15) which may also have been influenced, at least in part by the administering of experimental drugs.

Acute Respiratory Distress Syndrome (ARDS): definition and possible causes

The definition of Acute Respiratory Distress Syndrome (ARDS) in adults was first described in 12 patients aged from 11 to 48 years by Ashbaugh A, assistant professor of surgery from the department of surgery and medicine, University of Colorado Medical Center in Denver Colorado as first author (101). The patients were admitted to the ICU because of multiple trauma with or without lung contusion (4 cases), abdominal shotgun wound (1) or of the chest (1), one patient had acute pancreatitis,

Although 4 patients were suspected (according to the question mark used in the table 1 of the article) to have viral pneumonia, a history of viral infection was not reported.

Two patients had ingested drugs and possibly aspiration took place (101). Patients suffered of acute tachypnoea, hypoxaemia and did not respond to the conventional methods of respiratory therapy.

Distress developed as early as 1-96 hours after the triggering episode.

Acidosis was observed in four patients before respiratory distress developed.

Central venous pressure values were measured but results were not reported in the article.

The clinical and pathological features were supposed to closely resemble those observed in children with acute respiratory distress and those with „congestive atelectasis“ and postperfusion lung.

Authors found that positive end-expiratory pressure was very helpful against atelectasis, improving hypoxemia.

Also corticosteroids seemed to be of possible help in the case of young men with polytrauma and fat embolism and possibly some cases of suspected viral pneumonia.

A common finding was a diffuse alveolar „infiltration“ on chest X-ray.

None of the patients had previous serious lung disease.

Hypotension of various degree was observed in 5 patients and indicated as suffering of shock.

Four of those patients were estimated to have fluid overload from three to 7.5 liters.

Fluid overload was diagnosed in three more patients.

Chest-X-ray showed from patchy infiltrate to confluent patchy infiltrate to consolidation areas as an ominous sign predicting death.

No clinical chemistry data were given and no routine drug administration was reported. In fact, most of the attention was centered on pulmonary pathophysiology and no other data during the follow-up were given.

The possible role of the induction of positive end-expiratory pressure to avoid the hypothesized collapse of the alveoli (as cause of atelectasis) was discussed in 5 cases.

In fact, three of the five cases treated with positive end-expiratory pressure survived, compared to two of seven without this treatment.

The authors concluded that the procedure may serve to gain time for treatment of the underlying process which will contribute to reverse the bad prognosis.

At autopsy (seven cases) the average weight of the lung was 1150 grams for the right and 960 for the left lung. The colour of the organ was reddish-purple as sign of blood accumulation. At that time the explanation for the massive reduction of functioning alveoli was atelectasis, in spite of the blood engorgement (sequestration) responsible for the massive increase of the organ weight.

In one case, the histological study showed engorgement of the alveolar capillaries and in case 1 intralveolar haemorrhage and edema was observable (101).

Many macrophages and **hyaline membranes** were found within the alveolar area in all but one patient.

In 1994 the first American-European consensus conference defined 4 key components to allow the definition of ARDS:

a) acuteness of the respiratory distress defined as b) hypoxemia measuring the arterial partial pressure of oxygen divided by the fraction of inspired oxygen ($\text{PaO}_2/\text{FiO}_2$ less than 200 mmHg), c) bilateral infiltrates must be present on a X-ray of the chest, d) the findings should not be due to cardiac insufficiency as measured by using the pulmonary artery catheterisation (pulmonary capillary wedge pressure > 18 mmHg).

As this procedure is not easy to perform in a surgical ICU, it fell from favor (102).

In fact, it was removed when the „Berlin Criteria“ were decided by the European Society of Intensive Care Medicine (103). At that conference data set of 4.188 patients with ARDS from 4 multicenter clinical data sets in addition to data sets of 269 patients from 3 single centres from Europe, USA and Australia with presumed ARDS, of pulmonary and non pulmonary etiology, were used.

The definition of „acute“ given to respiratory distress beginning one week or less after the triggering episode (inciting insult) was chosen to replace „acute lung injury“. It was however defined as a type of acute diffuse, inflammatory lung injury, leading to increased pulmonary vascular permeability, increased lung weight and loss of aerated lung tissue (103).

A further diagnostic criterium was bilateral chest X-ray infiltrates (as assessed by CT-scan of the chest) not fully explained by fluid overload or heart failure (103). The list also contained the respiratory criteria for definition of severity grade of the hypoxia under mechanical ventilation.

Although fluid overload (and total lung weight) is of utmost diagnostic importance and can be measured by CT-scan, there was no consensus for mentioning it in the list of the criteria for illness severity (103).

Instead, it was decided that patients may qualify as having ARDS as long as they have respiratory failure not fully explained by cardiac failure or fluid overload as judged by the treating physician using all available data (e.g. use of the echocardiography).

In that conference it was reported that among the 4.188 patients those treated in academic centers had the worst prognosis and the lowest number of trauma patients (103).

The three categories of ARDS severity, mild, moderate and severe, could be used for therapeutic trials and eventually for resource allocation and also to decide whether to pursue ICU-treatment or not.

It was certified that according to the Berlin definition of ARDS, 29% of the patients with mild ARDS at baseline progressed to moderate ARDS and 4% further progressed to the severe form of the disease. In addition, 7% of moderate ARDS progressed to the severe form (103). It was stated that using the Berlin definition the different clinical stages (mild, moderate, severe) had significantly different increased lung weight 1371 g, 1556 g and 1828 g for both lungs respectively. This parameter was not added to the definition characteristics most probably due to difficult practicability.

No special mention of a possible explanation for non-cardial fluid (blood) accumulation in the lungs can be found in the Berlin Definition of ARDS and

pathophysiology of lung weight increase continues to be disregarded at the clinical and at the autopsy level.

In fact, most of the discussions concentrated on the microscopic finding of diffuse alveolar damage (DAD) with the presence of hyaline membranes within the alveoli which has been considered to be the hallmark of ARDS and of the previous Respiratory Distress Syndrome in children and adults (23, 104-110) independently of the etiology of ARDS.

In a retrospective (1991-2010) pathology study applying the Berlin definition of ARDS with the addition of refractory shock (45% of the patients) and of refractory hypoxemia (11%) during the last 6 hours before death(111), hyaline membrane and the other DAD-characteristics were found in overall 45% of the cases independently of the origin (pulmonary,non-pulmonary) of ARDS .All the patients, including those with cardiogenic pulmonary edema (non-ARDS) had increased lung weight ,1693 g and 1313 g for ARDS and non-ARDS respectively.In that study an additional explanation for radiologic opacities, which could be due to atelectasis as higher inflation pressure for injecting the fixative formalin into the lung after removal ,was needed.

It remained to be explained the cause of increased lung weight (111) in absense of DAD .

In a further analysis of the 159 patients with the diagnosis of ARDS it was found that the exudative changes decreased with time of ventilation.In fact, 74 (90%)of 82 patients who died within one week of ARDS diagnosis had exudative changes while only 40 of 54 patients who died between one and 3 weeks after diagnosis and only four of 23 who died after more than 3 weeks after ARDS-diagnosis still had signs of exudation (112).Patients who had steroids had longer duration of mechanical ventilation and ARDS and fibrosis was more frequently of pulmonay origin. More patients were ventilated for more than 3 weeks in the sccond decade (2000-2010).Thirty-eight patients(24%) had thrombossis of the small pulmonary vessels.

Unfortunately only the lungs of the 356 out of the 712 patients with approved autopsy were analysed (111,112).

Although the study gave the oppurtunity to underline the importance of using low tidal volume to prevent occurrence of ARDS in ventilated patients as suggested by the Berlin definition in the ICU it represented an additional opportunity to realize that there was more research work to be done to improve the Berlin definition of ARDS.

The cause of DAD together with the exudative changes,and microthrombosis , the great „sequestration“ of the blood in the lung vessels were not discussed (112).

In the last decades, attempts to better differentiate the etiology and clinical pictures of ARDS with the hope to individualize therapeutic efforts have been undertaken (99,113-127).

Many efforts have been invested by searching for characteristics of severely ill patients which may predict developement of ARDS recently defined as Lung Injury Prediction Score (mostly for ventilated patients) (128-138) and help to prevent it.

Among others,shock,aspiration,different traumas but also alcohol use,chemotherapy but also hypoalbuminemia and use of different drugs including furosemide,the strongest diuretic drug available, were found to be of prognostic value for development of ARDS (99).

At the same time a new approach was developed by the group of Calfee C et al.(139) by retrospectively analysing the data of 1022 patients from two previous trials the ARMA(120-122 recruiting period 1996-1999)- and the ALVEOLI(123-127 recruiting period 1999-2002)-study.

Authors identified two subphenotypes of patients according to their inflammatory markers. Subphenotype 2 the hyperinflammatory phenotype showed higher plasma concentration of inflammatory biomarkers, higher prevalence of vasopressor use, lower serum bicarbonate level and higher prevalence of sepsis than phenotype 1. Phenotype 2 mortality was higher than phenotype 1. The serum level of albumin was dramatically low (2.2/2.1 gr/dl) in both groups of patients. In both cohorts more than 35% of the patients had pneumonia-induced ARDS with no clear indication for the cause (bacterial or viral) of the disease. A list of the administered drugs (sedatives, vasopressors and steroids) was not given.

The article was followed by the report of a study on the treatment of patients with ARDS and sepsis with rosuvastatin as potential inhibitor of inflammation (140) and controls. The study was stopped after two-third of patients were recruited because there was no difference in 28 days mortality between the two groups. Seventy% of the enrolled patients had pneumonia and 339 of 745 of the patients had shock at baseline. Albumin serum level and sedation drugs and the other administered drugs were not given.

In a further study (HARP-2-study), 259 patients with ARDS (62% pneumonia and 41 % sepsis) were treated with 80 mg/day simvastatin and 280 were studied as control group. No difference was found in 28 mortality rate and no difference in the mean number of ventilator-free days between the two groups (141).

Only CRP-serum level was monitored as inflammation marker (141).

Bos LD and coworkers (142) studied the blood samples collected from patients with ARDS from 2011 to 2013 around day of ARDS-diagnosis. The ventilation conditions were: a) low tidal volume, higher positive end-expiratory pressure levels and prone position (severe ARDS), restrictive fluid protocol and analgo-sedation with preference for bolus versus continuous administration.

Plasma from the blood samples of 700 patients was frozen at -80C and then analysed for 20 biomarkers of inflammation, coagulation and endothelial activation (142). Sixty-eight per cent of the patients had a medical indication for ICU treatment, 60 % had pneumonia- and 64 % had sepsis-ARDS. Patients had mild (37%), moderate (47%) and severe (15%) ARDS and mortality was 26%.

Based on 4 markers, IL-6, IFN-gamma, angiopoietin 1,2 (ANG1,2) two groups of patients were identified. Cluster 1 was defined as „uninflamed“ and cluster two as „reactive“. The reactive phenotype of the validation cohort had a significantly higher ICU- mortality (36.4%) compared to the uninflamed (15.6%). Interestingly, the mortality was independent of severity of ARDS based on the Berlin definition. Although the D-dimer plasma level was higher in the reactive group of patients, the difference was not higher enough to be of significant importance. Albumin-plasma mentioned among the routinely available variables was shown to have the same accuracy of the four biomarkers (shown in figure 3 of the article) as it was the case for bicarbonate plasma level. The patients of the reactive group had a lower albumin- and a lower bicarbonate-plasma-level compared to the uninflamed validation group. The albumin plasma level of the training group was even lower than that of the validation group. Authors mention that the biomarkers could be helpful to test therapeutic interventions such as

corticosteroids or macrolides. A possible correlation between the low albumin plasma levels and the increased plasma level of IL-6, PAI, ANG1,2 positive acute phase proteins could provide the explanation for the question of the cause of the increased plasma level of the 4 biomarkers.

Measurement of concentration of inflammatory mediators in the bronchoalveolar lavage from subphenotypes of ARDS (26 patients) did not show quantitative differences between „uninflamed“ and „reactive“ cohort, suggesting a difference between the systemic- and pulmonary-compartment (142).

The HARP-2-study was reanalysed as non-US study population, and furthermore on the basis of the inflammatory status (143).

For this reason additional inflammatory (IL-6- and soluble TNF-receptor-serum level) data were extracted from the patients data set. Sixty-one % of the patients in the hypoinflammatory group (353 patients) had pneumonia, compared to 43% in the hyperinflammatory (186) group. Eighty-one per cent of the hyperinflammatory group needed vasopressors and creatinine serum-levels in the patients of this group were significantly higher (1,7 mg/dl) than that in the hypoinflammatory group (0.85 mg/dl). The authors found that simvastatin improved 28 and 90 day survival in the hyperinflammatory group.

Lawler PR and Fan E (144) suggested to consider the results of the retrospective non randomized study as exploratory and hypothesis-generating for prospective studies as it was also suggested by Heijnen et al (145).

A critical review of the latest literature about the actual value of subphenotyping of the various ARDS-patient cohorts concluded that prospective consistent identification of ARDS-subphenotypes are needed to better understand the underlying biology before one can decide to test which therapy may be more appropriate for the different cohorts (146,147).

A research workshop, by underlying the necessity to better identify subphenotypes of ARDS-patients concluded that the search for new effective treatments has been unsuccessful because of the heterogeneity of the causes and the biology of syndrome. It seems however appropriate to add measurement of blood volume and normalisation of albumin serum level to the list of the additional treatable traits (148).

Based on these experiences a study was performed on SARS-CoV-2 positive patients treated in the ICU with 20 mg atorvastatin/day. Two hundred-ninety patients were assigned to the atorvastatin, 297 to the placebo group, then followed for 30 days. The median length of ICU-stay was 5 days. Ninety-two percent of the patients received corticosteroids. Mortality was 31% and 35% in the atorvastatin and in the placebo group, respectively. The median duration of ventilator-free days was similar. Venous thrombosis frequency was similar as it was frequency of renal replacement therapy (149).

The question still remains what causes lung „edema“ as supposed by imaging and by histopathology, especially when pneumonia is the primary diagnosis, which is accompanied by sepsis and by the need for vasopressors.

A further prognostic marker introduced by recent publication could be the following: Not all patients with ARDS present the classic histologic changes, namely diffuse alveolar damage (DAD) and presence of hyaline membranes (111,128) in the alveolar wall in close contact with the capillaries. Those patients without DAD may have a better prognosis. A suggestion to modify the definition of ARDS has been published recently to differentiate respiratory distress due to diffuse alveolar damage (DAD) and that without DAD.

An attempt has been also made to further characterize the causes of the clinical situations leading to the development of hypoxia accompanied by the typical radiologic findings of ARDS resulting in the histologic picture of DAD.

While „conservative“ fluid administration is suggested in critically ill children (150) and in adults with ARDS because of the fear of more fluid entering into the alveoli (151), the dilemma of this decision is influencing indication for mechanical ventilation and survival of many hospitalized patients, as the need for it is also influenced by blood pressure (152).

Although many autopsy-studies of patients who died with ARDS report a two- to 5-fold increase of the weight of both lungs, they mainly concentrate on histology findings especially on DAD, presence of hyaline membranes and microthrombi in the capillary, the question of the sequence of events however is seldom addressed (153-159).

In spite of the fact that DAD, hyaline membranes and microthrombi are not specific for COVID-19 victims (160) and that viral particles are not diffusely found in the lung at the microscopic level, the possible link between the need for vasopressor administration due to hypotension, the endothelial and hypoxic tissue damage (161) and the early appearance of DAD has not been discussed so far.

Hypotension due to hypovolemia also explains the quite frequent presence of tubulus necrosis in the kidney, also frequently found in SARS-CoV-1 (162), MERS-(163) and COVID-2 victims (164).

Hypotension due to hypovolemia may also be the explanation for

the disturbed sublingual microcirculation observed in severely ill ICU-patients (165-167) as it has been observed in severely ill patients infected with the influenza A (H1N1) -virus (118). In a further attempt to reclassifying ARDS these findings were not considered, but lung functional and radiologic parameters were the basis for the new definition (168).

This continues to be the case in a recently published effort to reconsider the pulmonary changes occurring during development of COVID-19- pneumonia (169); a new definition of the COVID-19-ARDS has been suggested namely CARDS. Patients were divided in 5 groups according to the revised Berlin definition of ARDS: a) non-CARDS, b) mild CARDS, c) mild-moderate CARDS, d) moderate-severe CARDS and e) severe CARDS according to their PaO₂/FiO₂ value (from >300 mmHg to <100 mmHg). The study concentrated on lung parameters including lung weight.




Figure S3: lung Computed Tomography (2-3 cm below the carina) extracted randomly from the non-ARDS, mild ARDS, mild-moderate ARDS, moderate-severe ARDS and severe ARDS. As shown, it is hard to find a relationship between the severity of the imaging and the severity of the hypoxemia.

Fig.4 CT-scan of the CEST of patients with ARDS of different severity (from 169 with permission). Only at a closer look opacities („shadows“) can be detected in the CT-scan of the patient with severe ARDS.

Surprisingly the D-dimer plasma levels reported were measured at baseline (overall range of 140 patients=215-411 ng/dl). The plasma levels of D-Dimer did not vary significantly within the different severity groups (169). The changes of D-Dimer plasma levels in the 14 patients (of 140) who died were not reported but there was no significant correlation with outcome. In this study the CT-scan result did not correlate with hypoxemia (Fig.4). Contrary to the literature data concerning the increase of lung weight proportionally to the severity of ARDS, in CARDS-patients the lung weight in moderate-severe and severe cases was 50% of the weight reported for non COVID-ARDS. This finding is surprising as the CARDS fulfill the Berlin definition criteria on the one hand and, on the other, the autopsy data also do not allow a differentiation between „pneumonias“ of different origin.

Only the total lung stress and not the lung weight is correlated with negative outcome.

Death occurred only in mechanically ventilated patients.

The conclusions of the article were critically commented by Neetz B et al. (170)

Furthermore, in most of the autopsy studies published so far, a multi-fold increase of lung weight has been regularly found in hospitalized COVID-19-patients who died of the disease. It remains therefore difficult to allocate the groups of patients with different oxygenations ($\text{PaO}_2/\text{FiO}_2$ from 226 to 83 in moderate-severe to 65 in severe ARDS) and significantly different FiO_2 but no different pH. It remains also difficult to understand the indication for mechanical ventilation, 4 to 9 days after admission, which was justified by the progression of respiratory distress.

The list of 34 different reasons reported by the attending physician who decided mechanical ventilation in 34 patients does not contribute to better understanding. Respiratory rate was 30 and above in 9 of the 10 patients where this information was reported but these numbers can not be found elsewhere in the tables of the article.

Quite often „agitation, intolerance“ to CPAP or NIV or delirium were reported as an additional reason for the intensivist to indicate mechanical ventilation at different times

after hospitalisation. Information about drugs administered before patients were admitted to the high-dependency unit (e.g. high dose corticosteroids and /or diuretics) and other supporting measures could help to better understand the peculiarities of this „subgroup“ of COVID-19 patients (age range 51-69 year) especially the changes of the esophageal pressure swing. Also administration of 6 mg dexametasone may be responsible for uncontrolled behaviour of the patients under certain conditions.

Dehydration could also have contributed to the „changes“ of mood and cognition (171)

Only septic shock was one of the reasons, which allows to think of a primary cause outside of the lung. In a second patient acute kidney injury was mentioned together with agitation during CPAP, PaO₂/FiO₂ 77 mmHg.

It remains difficult to think about the cause of death in the 14 patients, who died in the San Paolo Hospital in Milan without an anatomical correlate, if one does not have additional clinical data including blood volume together with serum albumin concentration and the list of the drugs administered before and during mechanical ventilation. Autoptic findings would also be of great help.

By measuring sublingual microcirculation for vessels smaller than 20 micrometers in 12 severely ill COVID-19-patients Damiani et al. (167) found an inverse correlation between the plasma level of D-Dimer, the perfused vessel density and the PaO₂/FiO₂-value (205). In that study D-Dimer plasma level ranged between 717 and 5536 ng/ml.

An inverse correlation between plasma level of D-Dimer and microcirculatory changes was found also in the retinal vessels of severe COVID-19 infected patients (172,173). This indicates once more that the changes observed in the alveolar capillaries and those observed in other territories (174) may be attributable to the same noxae, namely dehydration conditioning tissue oxygenation followed by the emergency induction of the perivascular clotting process.

The „conservative“ fluid administration also influences the nutritional part of the care of the hospitalized and especially of ventilated COVID-19-patient. In fact, in the latter case, intensivists are reluctant to administer calories and amino acid solutions intravenously because of the possible volume overload.

On the other hand, vasopressors to sustain systemic circulation and diuresis are administered regularly in severely ill patients (139).

In addition, these vital questions are discussed without considering that normal albumin serum level (3,5-5 gr/dL) is essential for assuring normal blood volume, to guarantee normal erythrocyte circulation, especially in the alveolar capillaries. This aspect of the clinical picture in severely ill patients at the ICU has not been considered when therapeutic options were discussed in ARDS-subphenotypes (139,143). In the hyperinflammatory group, in fact, systolic pressure was under 90 mm Hg and the use of vasopressors was frequent. The discussion about liberal or conservative fluid support can not be productive if albumin serum level is not considered (149,150,166).

Conservative fluid administration is routinely associated with furosemide administration ,to assure sufficient urine production.This strategy however leads to hypovolemia nad hypotension wich brings into play vasopressors in the attempt to reduce hypotension.Vasopressors however can even worsen the ischemic consequences in the tissues be responsible for the local release of acute-phase cytokines (e.g. IL-6) by the recruited macrophages and for the local and hepatic production of chemokines (e.g. IL-8) (58) and other acute-phase proteins.

Under normal conditions, a person of 70 kg body weight needs about 2.900 milliliter of water every day.About 700 ml of this water is necessary to preserve the Alveolar Lining Fluid (Table) and to avoid dryness of the mucosa of the upper respiratory tract. Every day that amount of fluid is expired with the air.

TABLE:Physiological functions of Alveolar Lining Fluid and consequences of its reduction

ALVEOLAR LINING FLUID (ALF):A PROTECTION LAYER

- liquid sheet of 0.2 um height
 - total amount in the lung alveoli = 36 ml
 - it covers the surface of the alveolar epithelial cells (AEC I,II,0,1-02um)
 - it contains surfacant protein B (SP-B)* produced by AEC II.SP-B avoids the collaps of the alveolus by reducing the surface tension at the air-liquid interface.
 - it avoids desiccation of AECs due to direct exposure oft he cells to air
 - it is continously maintained by water supply from the capillaries and/or interstitium or
 - by fluid reabsorption from the apical side oft he alveolar epithelium to the interstitium and drained by the lymphatic system.
 - it protects from particles,irritants and pathogens
 - it constitutes the enviroment oft he alveolar macrophages
 - it contains defensines
-

ALVEOLAR LINING FLUID (ALF): A PROTECTION LAYER (continuation)

-modification of the height and composition of the ALF

will impact the rate of O₂/CO₂-diffusion

-reduction of O₂-diffusion first induces an „ischemic“

Reaction and recruitment of inflammatory cells which will then worsen hypoxia

-reduction of SP-B* induces an increase of pressure on the capillary and can induce a collapse of it

-reduction of the amount of fluid leads

to a damage of the AECs on the alveolar side and to

a shrinkage of the endothelial cells on the capillary

luminal side.

-The latter allows plasma to invade the

alveolar lumen and triggers the „provisional clot“-

formation (hyaline membrane) as a protective measure to avoid further extravasation of plasma into the alveolus

-inflammatory reaction further reduces gas-exchange

*SP-B=surfactant protein B

This water originates from the alveolar capillary fluid which is kept constant, indicating that the fluid volume of the alveoli is replaced about 20 times/day (175).

To understand the possible cause of the changes occurring in the alveoli before DAD develops, it is important to recall the anatomical and functional peculiarities of the lung.

As the kidney needs water to exert its function as well as the brain needs sugar, the lung needs water and oxygen (176) to fulfill its function. Oxygen from the inhaled air is transferred to the erythrocytes through the wall of the alveolar capillaries replacing CO₂ which will be expired. To this aim alveolar tension has to be reduced to 0.

Similarities between the hepatic and the pulmonary circulation

The circulation of the lung resembles that of the liver. While the venous (portal circulation) blood reaching the liver transports nutrients through the venous blood from the intestine and hormones from the pancreas to the liver representing about 70% of the blood, the remaining 30% of blood flows into the liver from the hepatic artery. The wall of the liver sinusoids is anatomically predisposed to allow quick passage of nutrients from the intestine through the fenestrated endothelial cells (sieve plates) and to be quickly taken up by the hepatocytes. The wall of the sinusoid is made of the prolongations of specialized mesenchymal cells (stellate cells) underneath the endothelial cells which however do not obstruct the close contact between the fluid content of the sinusoids and the hepatocytes.

The tissue macrophages however are located inside the sinusoidal lumen while the alveolar macrophages are outside the vessel but inside of the alveolar lumen to eliminate foreign bodies which eventually surpass the bronchial defense apparatus.

When continuous liver damage occurs, liver cirrhosis may develop and portal blood flow through the liver is strongly reduced. Portal hypertension is the consequence.

In this case, different amounts of venous blood are sequestered in the venous portal system as only a part of the portal blood can reach the cava through venous collaterals (e.g. esophageal varices). Reduced liver function and reduced albumin serum level, reduced systemic blood volume and ischemic damage in the intestinal tissues are the consequence.

Administration of diuretics may reduce blood volume and blood pressure causing prerenal kidney insufficiency leading to the so-called hepatorenal syndrome.

In the lung venous blood from the right heart is transported by the pulmonary circulation, the pulmonary veins, to the pulmonary capillaries which build the borders of each alveolus. The second circulation is represented by the bronchial circulation originating from the aorta and from the intercostal arteries.

The pulmonary capillary vessels are much thinner than conventional arteries and their wall is so thin that fluid (see above) and gas can move across.

The capillary network of the alveoli builds a „sheet“ which allows to reduce flow resistance and favours gas exchange. The availability of the capillary segments may vary according to the transmural pressure difference between inside and outside of the vessels.

When this is slow many capillaries are closed. They may however be rapidly recruited to satisfy increased blood flow (low pressure high flow system). This flexibility is necessary as the lung can not control the cardiac output. When the capacity of the heart to pump venous blood into the lung is reduced, splanchnic stagnation of venous blood occurs.

When pulmonary congestion develops a reduction of blood volume takes place and the heart (right and left) has less blood volume to pump and change of the heart size may not be apparent at X-ray-study.

In the liver, when metabolic needs of the body increase, as it is the case when the need of acute phase proteins becomes an emergency, more „inactive“ hepatocytes are „recruited“ and the production of proteins in the hepatocytes within the liver lobule dramatically increases. To this aim an increase of amino acid delivery through the portal blood into the liver sinusoids takes place.

ARDS-experimental models (pulmonary hyaline membrane disease)

Many publications dealing with experimental acute lung injury (ALI), a definition used as a synonym of ARDS and having the DAD (inflammatory infiltrates, thickened alveolar septae and deposition of hyaline membranes) as histological basis, have been published in the last decades (177-181).

However no animal model was considered to reproduce all the pathologic features of human DAD which is characterized by: a) an early exudative phase accompanied by accumulation of neutrophils in the vascular, interstitial and alveolar spaces („neutrophilic alveolitis“), b) deposition of the so-called hyaline membranes due to the deposition of fibrin and other proteinaceous debris at the alveolar site, as a sign of the disruption of the alveolocapillary membrane, c) interstitial thickening and d) formation of microthrombi interpreted as evidence of endothelial injury and activation of the coagulation cascade.

The lack of reproducibility of the human ALI has been justified by the fact that the human pathology may be caused by a combination of factors which can not be reproduced in animal models (177-181).

Hyaline membrane formation (Figures 5, 6) was not in focus any more (97,101).

All the experimental models however concentrate on the functional lung damage and disregard the systemic consequences of the endotoxin administration caused by reduction of fluid and food intake resulting in blood distribution abnormalities and decreased glomerular filtration (179-181) or by the changes of gene expression not only in the lung but also in the organs including the liver (182). In those experiments expression of smooth muscle alpha-actin was reduced not only in the heart but also in the lung 24 hours after endotoxin administration in a dose-dependent manner. This has to be taken into consideration whenever lung myofibroblasts are studied using alpha-SMA as marker antigen (183) in damaged lungs of patients who died at different times after SARS-CoV-2-infection.

Also the decrease of CD31 (PECAM-1) gene-expression in the inflamed areas is most probably due to the local production of TNF-alpha, which downregulates PECAM-1-gene-expression in endothelial cells (184).

The appearance of fluid in the alveolar space due to changes of the capillary permeability is called „pulmonary edema“ definition which however generates a clinical prejudice as if it were due to simple diffusion classically happening in the case of cardiac overload when, contrary, to the ARDS situation, reduction of fluid administration and administration of diuretics are responsible for reduction of blood volume through the capillaries. Administration of fluid and albumin is essential to reestablish normal blood volume and normal oxygenation.

1941 a pivotal report was published by Harry A Davis (185) from the department of Surgery of School of Medicine of Louisiana State University and Charity Hospital of Louisiana at New Orleans in Archives of Surgery. He reported about the clinical and autopsic findings of a 42 year-old male patient who was admitted to the hospital because of intestinal obstruction and massive dehydration due to severe and frequent vomiting. The patient was clearly in a state of circulatory failure with a systolic pressure of 75 mmHg and a pulse rate of 120 per minute. The patient died four hours after admission. Besides a 28 cm length of dark red strangulated jejunum with signs of gangrene all the other viscera except the lung were reduced in weight. The lung was heavy and moist and numerous petechial hemorrhages were present in the visceral pleura. Microscopically the alveolar capillaries were markedly distended and filled with closely packed red blood cells.

Furthermore the alveoli were filled with fluid and extravasations of blood were present in many areas (185).

This experience stimulated the author to perform a study on seventeen dogs (6 dogs were studied as control group) with a body weight between 5 and 10 Kg. Twenty-five cc of sodium chloride/Kg body weight (25%) were injected subcutaneously into a hindleg.

Two or three hours after injection the blood pressure began to progressively decrease accompanied by a progressive increase of marked edema at the site of injection until death which occurred between 5 and 10 hours after injection.

Outside of the edematous area of injected muscle on the subcutaneous tissues elsewhere were dry and sticky.

While the left ventricle was empty, the right ventricle was filled with thick partially coagulated blood.

While the pleural cavities were dry the lungs were brick- and purple-red showing numerous petechial hemorrhages in the visceral pleurae. The surface of the lungs exuded dark venous blood after cutting. The alveolar capillaries were dilated with closely packed erythrocytes many of which were found in the capillary spaces as a result of the rupture of the capillaries.

Alveoli were filled with clear acellular fluid. The extent of the alveolar damage was correlated to the length of the shock situation.

The animals which died quickly had less alveolar fluid (edema) than those which survived longer to the hypotension.

In a few animals some macrophages were detectable in the alveoli.

Davis concluded that dehydration is sufficient to explain the changes observed, most strikingly in the skin, the lungs and the weight reduction of the other organs and that there was no need to suppose a role for „toxic“ substances.

He supposed instead, that hemoconcentration is accompanied by a great reduction of oxygen content in the blood.

First viral acute Respiratory Distress Syndrome as post-influenza „pneumonia“

There are similarities of the macroscopic and clinical changes described by Davis as a consequence of dehydration with those observed by Petersdorfer et al.(23)1959 in the lungs of patients who died of „post-influenza pneumonia“.

While the number of emergency clinic visits for non-respiratory illness remained constant, the number of respiratory illness increased sharply with a peak during the last two weeks in October when 170 and 157 were seen (23). It was the year 1957 when the Asian influenza epidemic arrived in New Haven in late September. Most of the infected persons had mild disease but 91 of those patients with pulmonary infiltrates, who were seen at the emergency facility of the New Haven Hospital were hospitalized during the six weeks period from October 1957. This was a six-fold increase of the hospitalisation number compared to that of the previous year.

Among the 53 male, 26 were older than 50 whereas 24 of 38 female were between the ages of 16 and 40. Authors commented these numbers saying that

old men were prone to develop pneumonia following influenza while female were most vulnerable during the child-bearing period.

Forty of 91 hospitalized patients were black, while only 15% of the medical ward patients were black. Bacteriological investigation demonstrated bacterial infection in 38 patients while the other 43 patients with radiological or autopsic

signs of „pulmonary infiltrates“ were diagnosed pneumonia of undetermined etiology. Ten patients were diagnosed as having an acute tracheobronchitis.

Virological diagnostics consisted in investigating blood samples for the hemoagglutination-inhibition test and throat lavage fluid for virus culture.

A fourfold increase of the hemoagglutinin-inhibition test was found in the blood


of most of the patients who were tested, independently of the supposed cause of the pneumonia suggesting that the Asian-influenza virus was causal factor in most of the patients.

Symptoms preceding the visit to the emergency room were quite similar whereby ninety per cent of the patients had fever from 38 to 39 degree Celsius.

In nineteen patients the body temperature was even higher at presentation and persisted 48 to 72 hours after admission.

Patients with comorbidities such as heart (including three patients with hypertension)- or chronic lung diseases, diabetes and alcoholism were found to be more susceptible to post-influenza pneumonia as it was the case for 10 pregnant women. Only 36 of the 91 patients were free of comorbidities or pregnancy. Eleven of the 91 patients died. Four of them (68, 72, 76 and 77 year old) were suffering from chronic diseases, the pneumonia played an important causal role in their death. The other seven patients who died were young healthy adults who succumbed to an infection characterized by: acute onset, high fever, severe dyspnea, leukopenia, bloody sputum, anoxia and circulatory failure. Autopsic findings in a 19 year-old student who died 48 hours after admission are as actual (186) as

pathognomonic. The macroscopy of the lungs showed edematous red organs with a weight twice the normal. Microscopy showed severe hemorrhagic pneumonia with necrosis and **hyaline membrane formation** (fig.5). The picture was very much similar to that observed by Berfenstam et al.(101) in the lung of rabbits intoxicated with O₂(Fig.6).



*Fig.5. Alveoli lined with **hyaline membrane**(arrow). Modified from Petersdorfer et al.1959(23). With permission.*




Fig.6 Hialyne membranes (periodic acid- Schiff staining) in the lung of a rabbit treated with oxigen.(from 101 with permission)

All the patients showed a similar clinical pattern with mild upper respiratory disturbances, systemic symptoms lasting for several days followed by fever, cough, dyspnea, bloody sputum and leukopenia. Authors underscored the fact that the pathologic picture consisting in acute tracheobronchitis, diffuse involvement of the pulmonary parenchyma, necrosis of the alveoli, hyaline membrane formation with acellular hemorrhagic exudate was quite uniform not only in the New Haven patients but also in those who died of the same disease in USA and in England.

This report suggests many similarities with the actual pandemic situation and also describes similar autopsic findings with the central histologic hallmark, namely the presence of the hyaline membranes, which were known to represent fibrin deposition (97-99) and has been reported not only in premature children in the placenta, in the lung of O₂-intoxicated guinea pig and rabbits (97,101) but also in human adults (102,103). As it was described by Fujikura (97) fibrin deposition can be observed not only in the lungs of newborns but also in normal term placenta (97) perivillous fibrin deposition in the placenta of COVID-19-positive pregnant women after delivery has been recently reported together with trophoblast necrosis and histiocytic intervillitis. The triad has been called SARCOV-2 placentitis (187).

Respiratory Distress Syndrome (pulmonary hyaline membrane disease becomes Acute Respiratory Distress Syndrome (ARDS))

Description of ARDS -cases by Ashbaugh and colleagues (94) and later in several other reports of ALI/ARDS-cases (132-146) are strikingly similar.

In an article dedicated to clinical and radiologic feature of pulmonary edema Gluecker and coworkers thoroughly describe the clinical characteristics of the „PERMEABILITY EDEMA WITH DAD and clearly describe the corresponding radiological pattern as determined by conventional X-ray or CT-scan of the chest (188).

It is clear from the beginning that this part deals with the clinical picture of ARDS, term used for acute or subacute pulmonary „lesions“ accompanied with hypoxemia.

It has to be made clear that: a) the lesions observed at radiography are not caused or influenced by heart failure and

b) ARDS occurs without an increase in pulmonary capillary pressure.

Authors divide ARDS in two major groups depending on the possible different etiologic mechanisms which may lead to their development:

a) ARDS due to an underlying (assumed) pulmonary disease and b) ARDS secondary to extrapulmonary disease which manifests with an interstitial edema and alveolar collapse.

Authors justify the differentiation with the different implications for

the treatment of patients for example in the cases of sepsis, acute pancreatitis, severe trauma, or blood transfusions compared to that due to a more directly induced damage of the alveolar and vascular endothelium of the lung resulting from the exposure of the cells to chemical agents, infectious pathogens (such as bacteria or viruses), gastric fluid or toxic gas supposed to destroy or severely damage the tissue.

ARDS may undergo three stages

a) the first stage is characterized by interstitial „edema“ (exudative) with a high protein content that rapidly fills the alveoli and is associated with hemorrhage and formation of hyaline membrane.

*The words **exudative**, **edema** or **pneumonia** are not radiologic findings but correspond to a deduction which is not always possible at the time the radiologic investigation is performed. The radiologist can only speak of ground glass opacity (GGO) without an apparent cardiologic cause.*

Furthermore there are early cases of ARDS without DAD (characterized by an „inflammatory“ infiltrate) which should not be called pneumonia.

One important differential marker between GGO of cardiac and non-cardiac origin, is the lack of the Kerley lines characteristic of increase of interstitial fluid of cardiac origin.

b) the second stage (proliferative) is characterized by the organization of the alveolar fluid (called exudate).

c)the third stage is characterized by formation of fibrotic septa.

At CT-scan, ARDS has a more peripheral and cortical distribution which may change by changing the position of the patient suggesting that atelectasis plays also a role in the inhomogenous (regional) appearance, which is more common in ARDS than in classical bacterial pneumonia.

It is interesting to learn that recurrent „exudative“ episodes can occur in the proliferative and fibrotic stages of ARDS resulting in a mixed radiologic picture (Fig.7)



Fig.7. CT-scan of the chest of the same patient described above. The study was performed three months after discharge from the intensive care unit. It shows a mixed radiologic picture as a result of ARDS and of two months of mechanical ventilation. Patient is now suffering of long-COVID 18 months after release from ICU.

Modern development of ARDS: combination of new imaging techniques and pathology.

In the last 20 years many efforts have been invested in using CT-scan of the chest as a further prognostic characteristic. Recently a Radiographic Assessment of Lung Edema (RALE) score has been introduced (189) to assess the extent and density of the pulmonary opacities in patients with different severity grades of ARDS (190). Also by using this method there was a positive correlation with more conservative fluid therapy, lower RALE-score and mortality.

The APACHE III-score (191) has been used to differentiate two groups of critically ill hospitalized patients participating to the different therapeutic forms, conservative versus liberal, based on clinical characteristics.

It has to be pointed out however that the clinical value of two very important parameters namely albumin and creatinin serum level were quite underestimated as only albumin serum level of 2.4 gr/dl scored 6 points and creatinin of 2.2 mg/dl 7 points of 107 total points while an albumin serum level of 2.8 gr/dl scored 0 points and a creatinin serum level of 1.8 mg/dl scored 4 of 45 total points. On this basis is difficult to estimate the effect of different fluid administration policies in patients who were evaluated because of increased amount of fluid in the lung (called edema) without knowing the blood volume.

Recently two dimensional (2D) and three-dimensional (3D) reconstruction of pulmonary vasculature by using CT-scan of the chest has been used to study changes of the vascular morphology (192) or the loss of vessels in smokers who had undergone lung resection because of lung cancer (193). Combination of histological and imaging data allowed the 3D-reconstruction of the pulmonary vasculature down up a vascular radius of 0.5 mm and to establish a correlation between changes of the vasculature as assessed by histology and as measured by CT-scan.

By means of new software, retrospective analysis of CT-scan of the chest allowed a 3D reconstruction of the pulmonary vasculature and to calculate the total volume of smaller pulmonary vessels including those with a cross-sectional area below 5 quadrat mm (BV5) in persons exposed to air pollution. It was found that higher exposure to ozone was associated with smaller vascular volumes of the small pulmonary vessels (194).

Recently a combination of hierarchical phase contrast tomography (HiP-CT) and pathology techniques has been used in 5 intact human organs and in a lung from a deceased donor infected with HuCoV-2, to study regional changes in tissue architecture of the lung (195). The study of the lung of a 54 year old patient who died of COVID-19 allowed to differentiate parenchyma deterioration in COVIDs (less deteriorated) and COVIDc (more deteriorated).

Although ARDS was supposed as cause of death in the infected patient, the available lung portion were the upper left lobe and a biopsy of the right upper lobe of the mechanically ventilated patient.

The classical histologic finding of ARDS was not described.

The same technology has been applied by Eckermann et al (196) in the analysis of 6 lung samples from patient who died of respiratory failure due to COVID-19.

A three dimensional representation of the classical findings of DAD was generated with impressive pictures of hyaline membranes adjacent to the epithelial lining, moderate lymphocytic infiltration and singular thrombi in small pulmonary veins were described.

Also samples with high amount of swollen, inflamed blood vessels and thick hyaline membranes were found. In some slices capillaries filled with erythrocytes were shown.

Although in the manuscript the macroscopy of the lungs was not mentioned all patients had heavy bluish, firm lungs with impressive congestion of the capillaries filled of packed erythrocytes (197). All patients died after different time after HuCoV-2 infection, presence/proliferation of viral particles however was not described.

It is in fact important to realize that HuCoV-2-infection is the **trigger** of pathophysiologic changes, which may not be later attributed to direct influence of the virus (198).

While there was no difference in the CT-characteristics at the hospital admission between the group with moderate type and the severe or critical type HuCoV-2-infected patients (88% had GGO), a difference could be observed in the second CT-scan of the severe/critical group which showed more frequently a lower (50% vs 82%) occurrence rate of ground-glass opacity (GGO), but a higher occurrence of crazy-paving pattern (75% vs 39%) and of consolidation (81%). The occurrence rate of pleural thickening or adhesion also picked

(100%) at the second CT-scan(199). Similar results were reported for the groups of the moderate or severe/critical patients at repeated CT-scans (200) by Huang Y et al.

Study of changes of pulmonary vascular volume during hospitalization may serve as biomarker of abnormal gas transfer after HuCoV-infection.

In fact, a switch from BV5 to BV5-10 or above BV10 was observable in patients with low diffusion capacity of carbon monoxide (low DLCO).

Measurement of diffusion capacity may become the most important functional test after HuCoV-infection resolution(201). The report further underlines the distribution change from the smallest to the larger capillaries/vessels.

How SARS-CoV-2-infection of the nose leads to cardiac arrest and death

Autopsies at the initial stage of the disease including analysis of the upper respiratory tract are seldom performed (202).

The autopsic findings did not show particular damage at the level of the organs other than the lungs (203-208) while the changes of the mucosa of the upper respiratory tract were not studied.




Fig.8 Macroscopic picture of a lung taken at post-mortem autopsy of a patient who was admitted at the Mount Sinai Hospital and died because of HuCoV-2-infection. The gross appearance resembles that of a solid organ with „patchy“ areas of consolidation(A). The microscopic picture (B) shows the „congestion“ of the alveolar capillaries, which may represent the initial episode of the lung changes accompanied by deposition of hyaline membranes (blue arrows) and liquid outflow from the capillaries into the alveoli most probably induced by dehydration. The pictures were taken from figure 1 of the article published by Bryce C et al. in Modern Pathology 2021;34:1456-1467(202).

The gross morphology as shown in figure 8 (panel A) and histology (panel B) of the lung regularly found in hospitalized patients who died after SARS-CoV infection, was very much

similar to that observed in the victims of the SARS-CoV-1 (158) as shown in figure 9. The macroscopic picture of the congested lung and microscopic picture of DAD with the classical hallmark of the presence of hyaline membranes was also very similar.




Fig.9. *Gross morphology (upper panel) from the lung of a patient who died after a SARS-CoV-1-infection shows a congested lung while the histology picture (lower panel) shows the hyaline membranes (blue arrows). Modified from Ding et al. (158)*

As acute kidney injury is a clinically ominous prognostic sign (50). It is of relevance to note that tubular necrosis as „marker“ of hypovolemic shock has been often found (205-207) in absence of viral replication.

In fact, viral infection has not been found in the kidneys although positive PCR-findings were described and viral particles were suggested (205) when electron microscopy technique was used, which however needs a long experience to check plausibility (207,208).

Ischemic signs were not only found in the kidney but also in the heart and in the brain (209).

Multifocal vascular injury but no viral particles was described in the brain of 13 patients who died (11 of them died suddenly and unexpectedly (209) Microinflammatory changes have been also described in the heart of 6 patients who died of COVID-19 (210) and also in the retina (211).

In situ-hybridisation using SARS-CoV-2-specific-RNA gave negative results.

In one other study, although in situ hybridisation and immunohistochemistry studies gave positive results for the presense of viral „material“ in cells of alveolar capillaries, viral particles were hardly detectable in those structures (212)

Multifocal areas of retinal microvascular ischemia associated with multiple bilateral cotton-wool spots have been described in the left eye (OCT-angiography) of a patient who developed pneumonia and was tested positive for COVID-19 (day 17 of illness) and the authors concluded that retinal microangiopathy can develop in the late-phase of SARS-CoV-2-infection and that similar changes „can be happening in other less-accessible organs“ (211) Gelsomina Mansueto stated in a short communication (213) „The lack of autopsy findings did not allow us to evaluate with greater serenity what was happening and to understand that the specific pulmonary histological pictures and the secondary multiorgan damage in the patients with comorbidities were very similar to those already observed for other viral infections“. She also underlines in her conclusion the importance of unspecific supportive measures to prevent complications which are not different from those caused by other viruses and can lead to multiorgan failure and death (213).

Although several metanalyses have been recently published about the autoptic reports of the last two years and all agree that the main changes can be found in the lung and that necrosis of the kidney tubulus is quite often described (212-214) the question of the cause of death (215) after infection of the nasal mucosa by the virus (216-222) has been clearly addressed by Hooper JD et al. (223). For death certification cause of death could be divided into :

1. primary and

2.contributing.

Acute respiratory disease was most often cited as the primary cause as „COVID-19 pneumonia“ or „acute lung injury“ in 75% of the cases.

In 25% of the cases where COVID-19 was not the primary cause of death COVID 19 was listed as a contributing cause in 6 cases.

In spite of the fact that 54% of the 135 decedents acquired acute kidney dysfunction and 35% acquired myocardial dysfunction, these organ disturbances were not reported as primary cause of death but mostly reported as a contributing cause of death.

There was however no explanation for the „fluid imbalances“ which likely contributed to the „congestion“ and to the 3- to 4- fold increase of the lung weight which was frequently reported on the one side and the acquired kidney injury with hallmark of the tubulus necrosis on the other .

None of the autptic studies reported about the amount of fluid found in the different organs and most importantly in the heart chambers and in the urinary bladder.

Human organs are made to 80% of water (224). Water is essential for the formation of the secretions of the salivary glands, of the stomach, of the liver and of the pancreas which allow food digestion and passage of nutrients from the intestine into the portal blood. Water is important for the secretion of the glands of the upper respiratory tract and of the bronchial mucosa which represent the main barrier against noxious agents present in the air(225).

This has to be taken into consideration when supportive measures to improve prognosis of COVID-19 patients are being considered (29,157,226-228).

Water is very important for the production of the surfactant factor in the alveoli which allows the passage of oxygen and of CO₂ at the level of the pulmonary capillary(61,212). The proper hydration status of the endothelial cells is extremely important to avoid shrinking of those cells in areas such as the lung capillary where the endothelial cell represents the barrier for the intravascular fluid and prevents passage of plasma components into the alveolus(29,156,171).

Of course water is of vital importance for the physiological excretory function of the kidney and for the proper function of the brain.

Thirst is the central sensation which is triggered when dehydration induces 1-2% of body mass loss (227).

This induces a wide range of extracellular (decrease of blood volume and arterial pressure) and intracellular (e.g increased plasma osmolality) changes and of stimuli.

With increasing age, dehydration can continuously develop by the reduced sense of thirst , reduced mobility and ,again, uptake of diuretics.“Chronic“ hypertonicity of the blood due to dehydration has been described in older people.It is a risk factor for morbidity and mortality and it has to be kept in mind when approaching an older patient (29,225), especially if fever above 38 degrees centigrade aggravates this condition when lasting several days.

The geriatric population faces two main hydration-related conditions which can lead to the need for help from the doctor namely:

- a)* dehydration when the total body fluid is significantly reduced compared to the age-specific hydration status (which is already reduced compared to that of the young) and
- b)* excess of body fluid (overhydration) when the amount of fluid in the body is higher than normal.

The stability of this equilibrium decreases with increasing age and a few hundred milliliters of fluid may switch the hydration status into the one or the other direction(224-226).

Fluid loss can be caused by exposure to higher temperatures without compensation, by use of diuretics and, more importantly, by protracted high fever and inadequate fluid intake.

Oral intake of fluid for compensating fluid loss under such conditions may be inadequate and prolonged, moderate intravenous fluid administration may become quickly necessary to revert the established compensatory mechanisms to the dehydration condition before homeostasis is reestablished.

The consequence of fluid loss from the body is the reduction of blood volume, hyperconcentration with appearance of symptoms like dizziness, confusion (or delirium, brain fog), seizure and eventually stroke and death (224,225).

Dehydration in addition to reduced blood volume and eventually hypoalbuminemia may be responsible for other ominous symptoms, namely hypoxia (226) but can also predispose to diffuse thromboembolism especially in the lung (226-230).

This phenomenon may be the cause of progressive „sequestration“ of blood and of the progressive weight gain of the lung and eventually for reduction of blood volume and weight reduction in other organs especially in the kidney(181) .

Reduction of blood volume leads finally to cardiac arrest, the definitive cause of death (215) comparable to what happens in cases of malignant hyperthermia where fluid loss causes shock with increased lung weight (231).

The Future of symptomatic HuCoV-2-infection is in Home Treatment for Hospitalisation Prevention

The best would be to prevent COVID-19-positive patients to need hospitalisation by keeping them under controlled treatment at home .Although the symptoms caused by HuCoV-2-infection of the upper respiratory tract have been very much similar to those caused by the other endemic 4 coronaviruses and by the different influenza viruses, no official recommendations for pharmacological treatment were delivered by the health authorities and this was justified mostly because of lack of prospective trials.

After the first phase of the pandemic, which caused hundred of deaths of doctors who attempted to deliver relief and save lives without availability of enough preventive cloths and masks .

general practitioners were not willing any more to visit patients at home.

A report about the results of an online survey among the 8.000 members of the Italian College of General Practitioners and Primary Care (SIMG) performed in the period from January first 2021 and February 8 2021 was published in March 20th 2021,(22).

Members of the society were asked the daily problems with the treatment of COVID-19 patients at home. The question how to treat

patients with fever was answered with the suggestion to use up to 3 grams paracetamol per day. The use of other drugs such as aspirin or ibuprofen was also recommended.

It was also recommended to monitor an appropriate state of nutrition and hydration.

Monitoring of body weight was not however recommended. The fact however that the suggestions were not brought into practice

allowed, in many cases, disease to progress to respiratory distress and weakness (most probably in those patients who continue to take anti-hypertensive drugs in spite of development of hypotension) and forced patients and relatives to seek help in emergency rooms, infectious disease wards and eventually ICU.

In a retrospective analysis Suter and coworkers found that early treatment of COVID-19 patients at home prevented hospital admission due to progression to respiratory distress and in over 90% reduction of numbers of hospitalisation days and treatment costs (18).

An important prospective study performed in Denmark should pave the way to act in this direction (19,20).

In that prospective study only 28 out of 378 COVID-19, symptomatic patients sought temporary support at the hospital or at a COVID assessment unit. Twelve of them belonged to the usual-care group (188 patients); their urgent care visits lasted from few hours to 6 days. In the PEP selfcare group (190 patients) urgent care visits were reported by 16 patients; the length of their visits lasted from two hours to three days.

At least in one case dehydration and not hypoxia was the cause of the visit.

This experience is of pivotal importance for different reasons:

1. the vast majority of symptomatic HuCoV-2 patients (378 of 8386 persons with positive PCR-test result) did not need hospitalisation and recovered without further treatment.
2. patients could seek help also in so called COVID-19 assessment units.
3. as no difference in respiratory scale was observed between the two groups, the secondary outcome, hospitalisation related to HuCoV-2-infection, may not be due to the direct viral effect.
4. participants were recommended to have sufficient intake of fluid especially when fever appeared and to take paracetamol not only to decrease body temperature in case of fever but also to reduce myalgia or headache (18)
3. none of the hospitalized patient died.

4.it may not be reproducible in all parts of the world as it may need a high cultural level, as the participants were tested for their „understanding“ of health informations and their knowledge about what to do and how to interact with health care providers.

REFERENCES

1. World Health Organisation (WHO). COVID-19 weekly epidemiological Update as march 25 2022.
2. COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-2021. *Lancet* March 10, 2022. doi.org/10.1016/S0140-6736(21)02796-3.
3. Adam D. COVID'S true death toll: much higher than official figures. Modelling suggests that by the end of 2021, some 18 million people had died because of the pandemic. *Nature* 2022;603:562.
4. Zhu N, Zhang D, Wang W et al. A novel Coronavirus from patients with pneumonia in China, 2019. *New Engl J Med*. 2020;382:727-733. DOI: [10.1056/NEJMoa2001017](https://doi.org/10.1056/NEJMoa2001017)
5. Li Q, Guan X, Peng D et al. Early transmission Dynamics in Wuhan, China, of a novel Coronavirus-Infected Pneumonia. *New Engl J Med* 2020;382:1199-1207. DOI: [10.1056/NEJMoa2001316](https://doi.org/10.1056/NEJMoa2001316)
6. Guan W, Ni Z, Hu Y et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *New Engl J Med* 2020;382:1708-20. DOI: [10.1056/NEJMoa2002032](https://doi.org/10.1056/NEJMoa2002032)
7. Ni M, Tian F-B, Xiang D-D, Yu B. Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19. *J med Virol* 2020;92:2600-2606. DOI: [10.1002/jmv.26070](https://doi.org/10.1002/jmv.26070)
8. Mo P, Xing Y, Xiao Y et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. *Clin Infect Dis* 2020 April 1. DOI: [10.1093/cid/ciaa270](https://doi.org/10.1093/cid/ciaa270)
9. Su L, Ma X, Yu H et al. The different clinical characteristics of corona virus disease cases between children and their families in China-the character of children with COVID-19. *Emerg Microbes and Infect.* 2020;9:March 12. DOI: [10.1080/22221751.2020.1744483](https://doi.org/10.1080/22221751.2020.1744483)
10. Liu W, Zhang Q, Chen J et al. Detection of Covid-19 in children in early January 2020 in Wuhan, China. *New Engl J Med*. 2020;382(14), April 2. DOI: [10.1056/NEJMc2003717](https://doi.org/10.1056/NEJMc2003717)
11. Shi Q, Wang Z, Liu J et al. Risk factors for poor prognosis in children and adolescents with COVID-19: A systematic review and meta-analysis. *EClinicalMedicine* 2021;41:101155. DOI:10.1016/j.clinm.2021.101155.
12. McCormick DW, Richardson LC, Young PR et al. Death in Children and Adolescents Associated With COVID-19 and MIS-C in the United States. *PEDIATRICS* 2021;148:e2021052273. DOI:
13. Griffin KM, Karas MG, Ivascu NS, Lief L. Hospital Preparedness for COVID-19: A Practical Guide from a Critical Care Perspective. *Am J Respir Crit Care Med*. 2020;201:1337-1344. DOI:10.1164/rccm.202004-1037CP.

14. Cook DJ, Marshall JC, Fowler RA. Critical Illness in Patients With COVID-19. Mounting an Effective Clinical and Research Response. *JAMA* 2020;323:1559-1560. doi: 10.1001/jama.2020.3633
15. Gattinoni L, Gattarello S, Steinberg I et al. COVID-19 pneumonia: pathophysiology and management. *Eur Respir Rev.* 2021;30:210138 DOI:10.1183/16000617.0138-2021.
16. Anker MS, Landmesser U, von Haehling S et al. Weight loss, malnutrition, and cachexia in COVID-19: facts and numbers. *Journal of Cachexia, Sarcopenia and Muscle* 2021;12:9-13 DOI:10.1002/jcsm.12674.
17. McCullough PA, Kelly RJ, Ruocco G et al. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. *The American Journal of Medicine* 2021;134:16-22.
18. Suter F, Consolaro E, Pedroni S et al. A simple, home therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study. *EClinicalMedicine* 2021;37:100941.
<https://doi.org/10.1016/j.eclim.2021.100941>.
19. Mollerup A, Larsen SC, Selmer Bennetzen A et al. PEP-CoV protocol: a PEP flute-self-care randomised controlled trial to prevent respiratory deterioration and hospitalisation in early COVID-19. *BMJ Open* 2021;11:e050582. doi:10.1136/bmjopen-2021-050582
20. Mollerup A, Henriksen M, Larsen SC et al. Effect of PEP flute self-care versus usual care early covid-19: non-drug, open label, randomised controlled trial in a Danish community setting. *BMJ* 2021;375:e066952. doi:10.1136/bmj-2021-066952.
21. CDC Centers for Disease Control and Prevention. Similarities and Differences between Flu and COVID-19. Signs and Symptoms. <https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm>
22. Donno DR, Grattagliano I, Rossi A et al. How to treat COVID-19 patients at home in Italian context: An Expert Opinion. *Infect. Dis Rep.* 2021;13:251-258. <https://doi.org/10.3390/idr1310028>
23. Petersdorfer RG, Fusco JJ, Harter DH, Albrink WS. Pulmonary Infections Complicating Asian Influenza. *Archives of Internal Medicine* 1959;103:107-116
24. Ambrosch A, Rockmann F. Effect of two-step hygiene management on the prevention of nosocomial influenza in a season with high influenza activity. *Journal of Hospital Infection* 2016;94:143-149. doi: 10.1016/j.jhin.2016.07.006
25. Buttingol M, Pires-Neto RC, Calciolari Rossi R et al. Airway and parenchyma immune cells in influenza A(H1N1)pdm09 viral and non-viral diffuse alveolar damage. *Respiratory Research* 2017;18:147. DOI 10.1186/s2931-017-0630-x

- 26.Xie Y, Bowe B, Maddukuri G, Al-Aly Z. Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study. *BMJ* 2020;371:m4677. DOI: 10.1136/bmj.m4677
- 27.Stookey JD, Allu PKR, Chabas D et al. Hypotheses sub-optimal hydration in the weeks before coronavirus disease (COVID-19) as a risk factor for dying from COVID-19. *Medical Hypotheses* 2020;144:110237. DOI:10.1016/j.mehy.2020.110237
- 28.Martines RB, Ritter JM, Matkovic E et al. Pathology and pathogenesis of SARS-CoV-2 Associated with fatal Coronavirus Disease, United States. *Em Infect Dis.* 2020;25(9):2005-2015. DOI: 10.3201/eid2609.202095
- 29.Shurink B, Radonic T, Barbe E, et al. Viral presence and immunopathology in patients with lethal COVID-19: A prospective autopsy cohort study. *Lancet Microbe* 2020; September 25. DOI: 10.1016/S2666-5247(20)30144-0
- 30.Rommelink M, De Mendonca R, D'Haene N et al. Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. *Critical Care* 2020;24:495 DOI: 10.1186/s13054-020-03218-5
- 31.Dorward DA, Russel CD, UM ICH et al. tissue specific immunopathology in fatal COVID-19. *Am J Resp Critic Care Med* 2021;203(2):192-201. DOI: 10.1164/rccm.202008-3265OC
- 32.Bryce C, Grimes Z, Pujadas E et al. Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. *Modern Pathology* 2021;34:1456-1467. doi.10.1038/s41379-021-00793-y.
- 33.Barezowska S, Lefort K, Ioannidou K et al. Postmortem Cardiopulmonary Pathology in Patients with COVID-19 infection: Single-Center Report of 12 Autopsies from Lausanne, Switzerland. *Diagnostics* 2021;11:1357. doi.org/10.3390/diagnostics11081357
- 34.Picone S. Vo`Euganeo, chiuso il bar della prim vittima italiana del Covid: viola le norme anti-contagion. *FANPAGE.it*. 15 gennaio 2021. <https://www.fanpage.it>.
- 35.Modi C, Boehm V, Ferraro S et al. Estimating COVID-19 mortality in Italy early in the COVID-19 pandemic. *Nature Communications* 2021;12:2729. <https://doi.org/10.1038/s1467-021-22944-0>.
- 36.Buonanno P, Galletta S, Puca M. Estimating the severity of COVID-19: evidence from the Italian epicenter. *PLOS ONE* 2020;15(10):e0239569. <https://doi.org/10.1371/journal.pone.0239569>.
- 37.Istituto Superiore di Sanita`. Epidemiology of public Health. Coronavirus. Characteristics SARS-CoV-2-positive deceased patients. 2021.
- 38.Verity R, Okell LC, Dorigatti I et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis* 2020; 20:669-677. DOI: 10.1016/S1473-3099(20)30243-7

39. Omori R, Matsuyama R, Nakata Y. The age distribution of mortality from novel coronavirus disease (COVID-19) suggests no large difference of susceptibility by age. *Sci Rep*. 2020;10:e16642. DOI: 10.1038/s41598-020-73777-8
40. Number of Coronavirus (COVID-19) deaths in Germany 2021 by gender and Age. *STATISTA* 2021 March 22.
41. Reilev M, Kristensen KB, Pottegård A et al. Characteristics and predictors of hospitalisation and death in the first 11122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. *Int J Epidemiol* 2020;49(5):1468-1481. DOI: 10.1093/ije/dyaa140
42. Modig K, Lambe M, Ahlborn A, Ebeling M. Excess mortality for men and women above 70 according to level of care during the first wave of COVID-19 pandemic in Sweden: A population-based study. *Lancet Regional Health-Europe* 2021;4:100072.
43. Straelin K, Wahlström, Walther S et al. Mortality trends among hospitalized COVID-19 patients in Sweden: A nationwide observational cohort study. *Lancet Regional Health_Europe* 2021;4:100054.
44. Rosenthal N, Cao Z, Gundrum J et al. Risk factors associated with in-hospital mortality in a US National sample of patients with COVID-19. *JAMA Network Open* 2020;3(12):e2029058. • DOI: 10.1001/jamanetworkopen.2020.29058
45. Sablerolles RSG, Lafeber M, van Kampen JAL et al. Association between clinical frailty scale score and hospital mortality in adult patients with COVID-19 (COMET). An international, multicentre, retrospective, observational cohort study. *Lancet Healthy Longev* 2021 February 9. DOI: 10.1016/S2666-7568(21)00006-4
46. Mostaza JM, Garcia-Iglesias F, Gonzalez-Alegre T et al. Clinical course and prognostic factors of COVID-19 infection in an elderly hospitalized population. *Archiv of Gerontol Geriatrics*. 2020;91:104204. DOI: 10.1016/j.archger.2020.104204 .
47. Mannu G. Milano, dalla Cina arrivano le mascherine anti-Covid per gli anziani musicisti di Casa Verdi. *MILANO TODAY*. 20 Aprile 2020. <https://www.milanotoday.it>
48. Bai J, Shi F, Cao J-J et al. The epidemiological characteristics of death with COVID-19 in the early stage of epidemic in Wihan, China. *Global Health Res and Policy* 2020;5:54. DOI: 10.1186/s41256-020-00183-y
49. Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. *New Engl J Med* 2020;383:1757-1766. DOI: 10.1056/NEJMcp2009249
50. Berlin DA, Gulik RM, Martinez F. Severe Covid-19. *New Engl J Med* 2020;383:2451-2460. DOI: 10.1056/NEJMcp2009575
51. Garibadi BT, Zaman J, Artrandi MK et al. Reinvigorating the clinical examination for the 21st century. *Pol Archiv Int Med* 2019;129(12):907-912. • DOI: 10.20452/pamw.15073
52. Jacobsen AP, Khiev Y-C, Murphy SP et al. The modern physical exam. A transatlantic perspective from the resident level. *Teaching and Learning Medicine*. 2020; DOI: 10.1080/10401334.2020.1724792

53. Kwee TC, Kwee RM. Chest CT in COVID-19: what the radiologist needs to know. *Radio Graphics* 2020;40:1848-1865. doi: 10.1148/rg.2020200159
54. Siemieniuk RAC, Barosko J, Ge L et al. Drug treatments for COVID-19: living systematic review and network meta-analysis. *BMJ* 2020;370:m2980. DOI: 10.1136/bmj.m2980
55. Ammassari A, Di Filippo A, Trotta P et al. Comparison of demand for drugs used for COVID-19 treatment and other drugs during the early phase of the COVID-19 pandemic in Italy. *JAMA NETWORK Open*. 2020;4(2):e2037060. February 8. DOI: 10.1001/jamanetworkopen.2020.37060
56. Wong CKH, Wan EYF, Luo S et al. Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohort: A propensity-score analysis. *EClinical Medicine* 2021. DOI: 10.1016/j.eclinm.2021.100743
57. Xu Z-S, Shu T, Kang L et al. Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients. *Signal Transduction and Targeted Therapy*. 2020;5:100. doi.org/10.1038/s41392-020-0211-1.
58. Sheikh N, Tron K, Dudas J, Ramadori G. Cytokine-induced neutrophil chemoattractant-1 is released by the noninjured liver in a rat acute-phase model. *Lab Invest* 2006;86:800-814. DOI: 10.1038/labinvest.3700435
59. Pruijt JF, Fibbe WE, Laterveer L et al. Prevention of Interleukin-8-induced mobilisation of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the Metalloproteinases gelatinase B (MMP-9). *Proc. Natl. Acad. Sci. USA* 1999;96:10863-10868.
60. Watanabe T, Kawano S, Kanamaru S et al. Endogenous Interleukin-8 (IL-8) Surge in Granulocyte Colony-Stimulating Factor-Induced Peripheral Blood Stem Cell Mobilization. *Blood* 1999;93:1157-1163.
61. Del Valle DM, Kim-Schulze S, Huang H-H et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nature Medicine* 2020;26:1636-1643. DOI: 10.1038/s41591-020-1051-9
62. Kox M, Waalders NJB, Kooistra EJ, Gerretsen J, Pickkers P. Cytokine levels in critically ill patients with COVID-19 and other conditions. *JAMA* 2020;324:1565-1567
63. Cotton JA, Platnich JM, Muruve DA et al. Interleukin-8 in gastrointestinal inflammation and malignancy: induction and clinical consequences. *International Journal of Interferon, Cytokine and Mediator Research* 2016;8:13-34.
64. Altschul DJ, Unda SR, Benton J et al. A novel severity score to predict inpatient mortality in COVID-19 patients. *Scientific Reports* 2020;10:16726. DOI: 10.1038/s41598-020-73962-9
65. Ayaz A, Arshad A, Malik H et al. Risk factors for intensive care unit admission and mortality in hospitalized COVID-19 patients. *Acute and Critical Care* 2020;35(4):249-254. DOI: 10.4266/acc.2020.00381
66. Nicholson CJ, Wooster L, Sigurslid HK et al. Estimating risk of mechanical ventilation and in-hospital mortality among adult COVID-19 patients admitted to Mass General Brigham: the

VICE and DICE scores.EClinical Medicine 2021 ;33:100765. DOI: 10.1016/j.eclinm.2021.100765

67.Bae S, Kim SR,Kim M-N et al.Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age:a systematic review and meta-analysis.Heart 2020;0:1-8. • DOI: 10.1136/heartjnl-2020-317901

68.Whetton AD,Preston GW,Abubeker S,Geifman N.Proteomics and informatics for understanding phases and identifying Biomarkers in COVID-19 disease.J Proteome res 2020;19:4219-4232. DOI: 10.1021/acs.jproteome.0c00326

69.Gulati A, Pomeranz C,Quamar Z et al.A Comprehensive Review of Manifestations of Novel Coronaviruses in the contest of Deadly COVID-19 Global Pandemic.Am J Med Sci 2020;360(1):5-34. DOI: 10.1016/j.amjms.2020.05.006

70.Calvo-Fernandez A, Izquierdo A, Subirana I et al.Markers of myocardial injury in the prediction of short-term COVID-19 prognosis.Rev Esp Cardiol 2020;xx(x):xxx-xxx.

71.Guisado-Vasco P, Valderas-Ortega S,Marravillas Carralon-Gonzales M et al. Clinical Characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral,antimalarials,glucocorticoids,or immunomodulation with tocilizumab or cyclosporine:A retrospective observational study(COQUIMA cohort).ECLINICALMEDICINE 2020;000:10591. DOI:https://doi.org/10.1016/j.eclinm.2020.100591

72.Maguire D, Woods M, Richard C et al.Prognostic factors in patients admitted to an urban teaching hospital with COVID-19 infection.J Transl Med 2020;18:354. doi.org/10.1186/s12967-020-02524-4

73.Izquierdo JL,Ancochea J,Savana COVID-19 research Group et al.Clinical Characteristis and Prognostic Factors for intensive care Unit-admission of Patients with COVID-19:Retrospective study Using Machine Learning and Natural Language Processing.J Med Intere t Res 202;22(10):e21801. https://www.medrxiv.org/content/10.1101/2020.05.22.20109959v1 ,

74.Boari G EM, Chiarini G, Bonetti S et al.Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia:a retrospective cohort study.Bioscience Reports 2020;40:BSR203455. , DOI: 10.1042/bsr20203455

75.Oussalah A,Gleye S, Clerc Urmes I et al.The spectrum of biochemical alterations associated with organ dysfunction and inflammatory status and their association with disease outcomes in severe COVID-19: A longitudinal cohort and time-series design study.ECLINICALMEDICINE 2020;000:100554. DOI: 10.1016/j.eclinm.2020.100554

98(26).Xie Y, Bowe B, Maddukuri G,Al-Aly Z.Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza:cohort study.BMJ 2020;371:m4677.DOI: 10.1136/bmj.m4677

76.Hwang J,Ryu H-S, Kim H-A et al.Prognostic factors of COVID-19 infection in Elderly Patients:A Multicenter Study.J Clin Med 2020;9:3932. DOI: 10.3390/jcm9123932

- 77.Izcovich A, Ragusa MA,Tortosa F.et al.Prognostic factors for severity and mortality in patients infected with COVID-19:A systematic review.PLOS ONE 2020;15(11):e0241955. DOI: 10.1371/journal.pone.0241955
- 78.Castro VM,McCoy THmPerlis RH.Laboratory Findings Associated with Severe Illness and Mortality Among Hospitalized Individuals With Coronavirus Disease 2019 in Eastern Massachusetts.JAMA NETWORK OPEN.202;3(10):e2023934. DOI: 10.1001/jamanetworkopen.2020.23934
- 79.Roberts I,Muelas MW, Taylor JM et al.Untargeted metabolomics of COVID-19 patient serum reveals potential prognostic markers of both severity and outcome.medRxivpreprint 2020 December11
- 80.Sise ME,Baggett MV, Shepard J-A O, et alCase 17-2020:A 68-Year-Old Man with COVID-19 and Acute Kidney Injury.New Engl J Med 2020;382(22):2147-2156. DOI: 10.1056/NEJMcpc2002418
- 81.Bowe B,Cai M,Xie Y et al.Acute kidney injury in a national cohort of hospitalized US Veterans with COVID-19.CJASN 2021;14-25.DOI.org/10.215/CJN.09610620.
- 82.Liu L, Xie J,Wu W et al. A simple nomogram for predicting failure of non-invasive respiratory strategies in adults with COVID-19:a retrospective multicentre study.Lancet Digit Health 2021;february 8 online. DOI: 10.1016/S2589-7500(20)30316-2
- 83.Heldt FS,Vizcaychipi MP,Peacock S et al. Early risk assessment for COVID-19 patients from emergency department data using machine learning.Scientific Reports 2021;11:4200. DOI: 10.1038/s41598-021-83784-y
- 84.Yan H, Lu S, Chen L,Wang Y et al.Multiple organ injury on admission predicts in-hospital mortality in patients with COVID-19.J Med Virol 2021;93:1652-1664. DOI: 10.1002/jmv.26534
- 85.Mitchell R, Baekyung Choi K,Pelude L et al.Patients in hospital with laboratory-confirmed COVID-19 in a network of Canadian acute care hospitals,Mar.1 to Aus.31,2020:a descriptive analysis.CMAJOPEN;2021;9(1):E149-E156.DOI: 10.9778/cmajo.20200246
- 86.Hariyanto TI,Valeriani Yapar K,Kwenandar F et al.Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection:A systematic review and meta-analysis.Am J Emer Med.2021;41:110-119. DOI: 10.1016/j.ajem.2020.12.076
- 87.Velavan TP,Meyer C.Mild versus severe COVID-19:laboratory markers.Int J Infect Dis.2020;95:304-307. DOI: 10.1016/j.ijid.2020.04.061
- 88.Garibladi BT,Fiksel J,Muschelli J et al.Patient trajectories among persons hospitalised for COVID-19.Ann Intern Med 2021;174:January DOI: 10.7326/M20-3905 .
- 89.Attaway AH,Sheraga RG,Bhimraj A et al.Severe covid-19 pneumonia:pathogenesis and clinical management.BMJ 2021;372:n436. DOI: 10.1136/bmj.n436

90. Heber S, Pereyra D, Schrottmaier WC et al. Development and external validation of a logistic regression derived formula based on a repeated routine hematological measurements predicting survival of hospitalized Covid-19 patients. medRxiv 2020 December 22.
91. Zhao Y, Quin L, Zhang P et al. Longitudinal COVID-19 profiling associates IL-6 and IL-10 with disease severity and CRP with mild disease. JCI Insight 2020;5(13):e139834. DOI: 10.1172/jci.insight.139834
92. Wohlgemuth S, Garibaldi BT, Antar AAR et al. Development of severe COVID-19 adaptive risk predictor (SARP), a calculator to predict severe disease or death in hospitalized patients with COVID-19. Ann Int Med. 2021;2 march
93. Huang J, Cheng A, Kumar R et al. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity. J Med Virol 2020;1-7:DOI:10.1002/jmv.26003. DOI: 10.1002/jmv.26003
94. Kim AY, Hirsch MS, Bloom A. COVID-19: management in hospitalized adults. UpToDate. Last update Nov 15 2021.
95. Orkin MA, Gill PJ, Ghersi D et al. Guidelines for Reporting Trial Protocols and Completed Trial Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances. The CONSERVE 2021 Statement. JAMA. 2021;326:257-265. doi:10.1001/jama.2021.9941
96. Tobin MJ, Jubran A, Laghi F. Noninvasive strategies in COVID-19: epidemiology, randomised trials, guidelines, physiology. Eur Respir J. 2021;57:2004247. https://doi.org/10.1183/13993003.04247-2020.
97. Burns KEA, Laird M, Stevenson J. Adherence of Clinical Practice Guidelines for Pharmacologic Treatments of Hospitalized Patients With COVID-19 to Trustworthy Standards: A Systematic Review. JAMA Network Open 2021;4(12):e2136263. doi:10.1001/jamanetworkopen.2021.36263
98. Birgand G, Mutters NT, Otter J et al. Variation of National and International Guidelines on Respiratory Protection for Health Care Professionals During the COVID-19 Pandemic. JAMA Network Open. 2021;4:e2119257. doi:10.1001/jamanetworkopen.2021.119257.
99. Ahmed AH, Littell JM, Malinchoc M et al. The role of potentially preventable hospital exposures in the development of Acute Respiratory Distress Syndrome: A population-Based Study. Crit Care Med. 2014; 42:31-39.
100. Paternoster G, Bertini P, Innelli P et al. Right Ventricular Dysfunction in Patients With COVID-19: A Systemic Review and Meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia 2021;35:3319-3324. doi:10.1053/j.jvca.2021.04.008.
101. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory Distress in Adults. The Lancet 1967; August 12 7511:319-323. doi: 10.1016/s0140-6736(67)90168-7

102. Bernard GR, Artigas A, Brigham KI et al. American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical coordination. *Am J Respir Crit Care Med* 1994;149:818-824.
103. Ranieri M, Rubenfeld GD, Thompson BT et al. The Berlin ARDS Definition Task Force. Acute Respiratory Distress Syndrome. The Berlin Definition. *JAMA* 2012;307(23):2526-2533.
104. Fujikura T. Histochemical studies of pulmonary hyaline membranes. *Keio Journal of Medicine* 1955;4:175-190
105. Gregg RH, Bernstein J. Pulmonary Hyaline Membranes and the Respiratory Distress Syndrome. *Progress in Pediatrics. Am J Dis Child*. 1961;102:871-890.
106. Robertson B. The relationship between hyaline membranes of the newborn and the presence of other pulmonary lesions. *Acta Paediatrica* 1963;52:569-574.
107. Fujikura T, Froehlich LA. The influence of race and other factors on pulmonary hyaline membranes. *Am J Obst Gynecol*. 1966;95:574-578.
108. Berfenstam R, Edlund T, Zettergren I. The hyaline membrane Disease. A review of earlier clinical and experimental findings and some studies on the pathogenesis of hyaline membranes in O₂-intoxicated rabbits. *Acta Paediatrica* 1958;47:82-100.
109. Capers TH. Pulmonary Hyaline Membrane Formation in the adult. A clinicopathological study. *Am J Med*. 1961;31:701-710.
110. Chapter 1: Hyaline Membrane Disease. *Acta Radiologica: Diagnosis*. 1967;6Sup262:7-12. DOI:10.1080/05678066709170515.
111. Thille AW, Esteban A, Fernandez-Segoviano P et al. Comparison of the Berlin Definition for Acute Respiratory Distress Syndrome with Autopsy. *Am J Respir Crit Care Med* 2013;187:761-767. DOI:10.1164/rccm.201211-1981oc.
112. Thille AW, Esteban A, Fernandez-Segoviano P, et al. Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies. *Lancet Respir Med*. 2013;1:395-401.
113. Thompson BT, Mathay M. The Berlin Definition of ARDS versus Pathological Evidence of Diffuse Alveolar Damage. *Am J Respir Crit Care Med* 2013;187:675-677. DOI:10.1164/rccm.201302-0385ED.
114. Hudson LD, Milberg JA, Anardi D, Maunder RJ. Clinical Risks for Development of acute Respiratory Distress Syndrome. *Am J Respir Crit Care Med*. 1995;151:293-301.
115. Estensoro E, Gonzalez F, Laffaire E et al. Shock on Admission Day is the best Predictor of Prolonged Mechanical Ventilation in the ICU. *CHEST* 2005;127:598-603. DOI:
116. Peres e Serra A, Parra ER, Eher E, Capelozzi VL. Nonhomogeneous Immunostaining of hyaline membranes in different manifestations of diffuse alveolar damage. *CLINICS* 2006;61:497-502.

- 117.Villar J Perez-Mendez L, Lopez HJ et al.An early PEEP/FiO₂ Trial identify different degrees of lung Injury in Patients with acute Respiratory Distress Syndrome.Am J Repir Crit Care Med.2007;176:795-804.
- 118.Salgado DR,Ortiz JA,Favory R et al.Microcirculatory abnormalities in patients with severe influenza A(H1N1) infection.Can J Anesth/JCan Anesth 2010;57:940-946.DOI 10.1007/s12630-010-9365-6.
- 119.Nin N, Sanchez-Rodriguez C, Ver LS et al.Lung histopathological findings in fatal pandemic influenza A(H1N1). Med Intensiva 2012;36:24-31.
- 120.The Respiratory Distress Syndrome Network.Ventilation With Lower Tidal Volumes As Compared With Traditional Tidal Volumes For Acute Lung Injury And Acute Respiratory Distress Syndrome.N Engl J Med 2000;342:1301-1308.
- 121.Tobin MJ.Culmination of an Era in research on the acute respiratory Distress Syndrome.N Engl J Med 2000;342:1360-1361.
- 122.Laffey JG,Kavanagh BP.Ventilation with lower Tidal Volumes as Compared with Traditional Tidal Volumes for acute lung injury.Correspondence.New Engl J Med.2000;343:812-814.
- 123.The National Heart,Lung and Blood Institute ARDS Clinical Trials Network.Higher versus Lower Positive End-Expiratory Pressures in Patients with the Acute Respiratory Distress Syndrome.N Engl J Med.2004;351:327-336.
- 124.Levy MM.PEEP in ARDS-How Much is Enough?.N Engl J Med.2004;351:389-
- 125.Perren A.High versus Low PEEP in ARDS.Correspondence.N Engl J Med.2004;351:2128-2129.
- 126.Rivers EP.Fluid-Management Strategies in Acute Lung Injury-Liberal,Conservative,or Both?N Engl J Med 2006;354:242598-2600.
- 127.Schuller D,Schuster DP.Fluid-Management Strategies in Acute Lung Injury.Correspondence.N Engl J Med.2006;355:1175
- 128.Gajic O,Dabbagh O, Park PK et al.Early Identification of patients at risk of acute lung injury.Evaluation of lung injury prediction score in a multicenter cohort study.Am J Respir Crit Care Med.2011;183:462-470.
- 129.Bauman ZM,Gassner MY,Coughlin MA, et al.Lung Injury Prediction Scope Is Useful in Predicting Acute Respiratory Distress Syndrome.Critical Care Research and Practice.2015;ID 157408.
- 130.Dries DJ.Acute Respiratory Distress Syndrome and Lung Protection.Air Medical Journal.2016;35:59-62.
- 131.Kao K-Ch,Chang Ch-H, Hung Ch-Y et al.Survival Predictor in Patients with acute respiratory distress syndrome and diffuse alveolar damage undergoing open lung biopsy.2017;PloSOne 2017;12(7):e0180018.

132. Zhao Z, Wickerham N, Kangelaris KN et al. External Validation of a biomarker and clinical prediction model for hospital mortality in acute respiratory distress syndrome. *Intensive Care Med.* 2017;43:1123-1131.
133. Famous KR, Delucchi K, Ware LB et al. Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy. *Am J Respir Crit Care Med.* 2017;195:331-338. DOI:10.1164/rccm.201603-0645OC.
134. Warren MA, Zao Z, Koyama T et al. Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes in ARDS. *Thorax* 2018;73:840-846. DOI:10.1136/thoraxjnl-2017-211280.
135. De Luca D. Personalizing care of acute respiratory distress syndrome according to patient's age. *Lancet Respir Med* 2018. DOI:10.1016/S2213-2600(18)30429-6.
136. Spataro S, Park M, Turrini C et al. Biomarkers for acute Respiratory Distress syndrome and prospects for personalized medicine. *Journal of Inflammation* 2019;16. DOI:10.1186/s12950-018-0202-y.
137. Maley JH, Thomson BT. Embracing the Heterogeneity of ARDS. *CHEST* 2019;155:453-455. DOI:10.1016/j.chest.2018.11.016.
138. Shenck EJ, Oromendia C, Torres LK et al. Rapidly Improving Acute Respiratory Distress Syndrome In Therapeutic Randomized Controlled Trials. *CHEST* 2019;155:474-482. DOI:10.1016/j.chest.2018.09.031.
139. Calfee CS, Delucchi K, Parsons PE et al. Latent Class analysis of ARDS subphenotypes: Analysis of data from two randomized controlled trials. *Lancet Respir Med.* 2014;2:611-620. DOI:10.1016/S2213-2600(14)70097-9.391.
140. The National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome. *N Engl J Med* 2014;370:23:2191-2200. DOI:10.1056/NEJMa1401520.
141. Bos LD, Schouten LR, van Vught LA et al. Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. *Thorax* 2017;72:876-883. DOI:10.1136/thoraxjnl-2016-209719.
142. Calfee CS, Delucchi KL, Sinha P et al. Acute Respiratory Distress Syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomized controlled trial. *Respir Med* 2018; DOI:10.1016/S2213-2600(18)3017-2.
143. Lawler PR, Fan E. Heterogeneity and phenotypic stratification in acute respiratory distress syndrome. *Lancet Respir Med* 2018. DOI:10.1016/S2213-2600(18)30287-X.
144. Heijnen NFL, Bergmans DCJJ, Schnabel RM, Bos LDJ. Targeted treatment of acute respiratory distress syndrome with statins-a commentary on two phenotype stratified re-analysis of randomized controlled trials. *J Thorac Dis* 2019;11(Suppl 3):S296-S299. DOI:10.21037/jtd.2019.01.23.

145. Hejineni NFL, Hagens LA, Smit MR et al. Biological subphenotypes of acute respiratory distress syndrome may not reflect differences in alveolar inflammation. *Physiological Reports* 2021;9:e14693. DOI:10.14814/phy.2.14693.
146. Reddy K, Calfee CS, McAuley DF. Acute Respiratory Distress Syndrome Subphenotypes beyond the Syndrome: A Step toward Treatable Traits? *Am J Respir Crit Care Med*. 2021;203:1449-1451. DOI:10.1164/rccm.202101-0218ED.
147. Bos LDJ, Artigas A, Constantin J-M et al. Precision medicine in acute respiratory distress syndrome: workshop report and recommendations for future research. *Eur Respir Review* 2021;30:200317. DOI:10.1183/16000617.0317-2020.
148. INSPIRATION-S investigators. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial. *BMJ* 2022;376:e068407. DOI:10.1136/bmj-2021-068407.
149. Inglese SA, Woesten-van-Asperen, Lemson J et al. Pediatric Acute Respiratory Distress Syndrome: Fluid Management in the PICU. *Frontiers in Pediatrics* 2016;4:DOI:10.3389/ped.2016.00021.
150. Vignon Ph, Evrard B, Asfar P et al. Fluid administration and monitoring in ARDS: which management? *Intensive Care Management* 2020;46:2252-2264.
151. Tobin MJ, Jubran A, Laghi F. Hypoxemia does not necessitate tracheal intubation in COVID-19 patients. *Comment on Br J Anaesth* 2021;126:e75-e76. doi:10.1016/j.bja.2020.11.007.
152. Cardinal-Fernandez P, Lorente JA, Ballen-Barragan A et al. Acute Respiratory Distress Syndrome and Diffuse Alveolar Damage. *New Insights on a Complex Relationship*. *AnnalsATS*. 2017;14:844-850.
153. Konopka KE, Nguyen T, Jentzen JM et al. Diffuse alveolar damage (DAD) resulting from coronavirus disease 19 infection is Morphologically Indistinguishable from Other Causes of DAD. *Histopathology* 2020;77:570-578. Doi:10.1111/his.14180.
154. Kommos FKF, Schwab C, Tavernar L et al. The Pathology of Severe COVID-19-Related Lung Damage.-mechanistic and Therapeutic Implications. *Dtsch Arztebl Int*. 2020;117:500-506. DOI:10.3238/arztebl.2020.0500.
155. Neil D, Moran L, Horsfield C et al. Ultrastructure of cell trafficking pathways and coronavirus: how to recognise the wolf amongst the sheep. *J Pathol* 2020;252:346-357. DOI:10.1002/path.5547.
156. Hopfer H, Herzig MC, Gosert R et al. Hunting coronavirus by transmission electron microscopy-a guide to SARS-CoV-2-associated ultrastructural pathology in COVID-19 tissues. *Histopathology* 2021;78:358-370. DOI:10.1111/his.14264
157. McMullen P, Pytel P, Snyder A et al. A series of COVID-19 autopsies with clinical and pathologic comparisons of both seasonal and pandemic influenza. *J Pathol Clin Res* 2021;7:459-470. DOI:10.1002/cjp.2.220.

158. Beasley MB. Acute lung Injury-from cannabis to COVID. Modern Pathology 2021 published on line 09 september. <https://doi.org/10.1038/s41379-021-00915-6>.
159. Menezes RG, Rizwan T, Saad Ali S et al. Postmortem findings in COVID-19 fatalities: A systematic review of current evidence. Legal Medicine 2021. doi:<https://doi.org/10.1016/j.legalmed.2021.102001>.
162. Basta G. Direct or indirect endothelial damage? An unresolved question. EBiomedicine 2021;64:103215. DOI: 10.1016/j.ebiom.2021.103215
160. Chang JC. Acute Respiratory Distress Syndrome as an Organ Phenotype of Vascular Microthrombotic Disease: Based on Hemostatic Theory and endothelial Molecular Pathogenesis. Clinical and Applied Thrombosis/Hemostasis 2019;25:1-20. DOI:10.1177/1076029619887437.
161. Karimova A, Pinsky. The endothelial response to oxygen deprivation: biology and clinical implications. Intensive Care Med. 2001;27:19-31. DOI:10.1007/s001340000790.
162. Ding Y, Wang H, Shen H et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol 2003;200:282-289. DOI:10.1002/path.1440.
163. Ng DL, Al Hosani F, Keating K et al. Clinicopathologic, immunohistochemical, and Ultrastructural Findings of a fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014. Am J Pathol 2016;186:652-658. DOI:10.1016/j.ajpath.2015.10.024.
164. Santoriello D, Khairallah P, Bomback AS et al. Postmortem kidney pathology findings in patient with COVID-19. JASN 2020;31:2158-2167. DOI: 10.1681/ASN.2020050744
165. Scorcella C, Damiani E, Domizi R et al. MicroDAIMON study: Microcirculatory DAILY MONitoring in critically ill patients: a prospective observational study. Ann. Intensive Care 2018;8:64. DOI:10.1186/s13613-018-0411-9.
166. De Backer D, Dadanello K, Taccone FS et al. Microcirculatory alterations: potential mechanisms and implications for therapy. Annals of Intensive Care 2011;1:27. DOI:10.1186/2110-5820-1-27.
167. Damiani E, Carsetti A, Casarotta E et al. Microvascular alterations in patients with SARS-CoV-2 severe pneumonia. Ann. Intensive Care 2020;10:60. DOI:10.1186/s13613-020-00680-w.
168. Maiolo G, Collino F, Vasques F et al. Reclassifying Acute Respiratory Distress Syndrome. Am J Resp Crit Care Med 2018;197:1586-1595. DOI:10.1164/rccm.201709-1804OC.
169. Coppola S, Chiumello D, Busana M et al. Role of total lung stress on the progression of early COVID-19 pneumonia. Intensive Care Med 2021;47:1130-1139. DOI:10.1007/s00134-021-06519-7.
170. Neetz B, Meis J, Herth FJF, Trudinski FC. Role of total lung stress on the progression of early COVID-19 pneumonia: collinearity and potential confounders. Intensive Care Med. 2021. DOI:10.1007/s00134-021-06557-1

171. Benton D Dehydration Influences Mood and Cognition. A Plausible Hypothesis?:
Nutrients 2011;3:555-573. DOI:10.3390/nu3050555.
172. Invernizzi A, Schiuma M, Parrulli S et al. Retinal vessels modifications in acute and post-COVID-19. Scientific Reports 2021;11:19373. DOI:10.1038/s41598-021-98873-1.
173. Hernandez M, Gonzalez-Zamora J, Reclade S et al. Evaluation of Macular Retinal Vessels and Histological Changes in Two Cases of COVID-19. Biomedicines 2021;9:1546. DOI:10.3390/biomedicines9111546.
174. Jidigam VK, Singh R, Batoki JC et al. Histopathological assessments reveal retinal vascular changes, inflammation, and gliosis in patients with lethal COVID-19. Graef's Archive for Clinical and Experimental Ophthalmology 2021. DOI:10.1007/s00417-021-05460-1.
175. Fronius M, Clauss WG, Althaus M. Why do we have to move fluid to be able to breathe?. Frontiers in physiology. 2012;3:art.146. DOI:10.3389/phys2012.00146.
176. Marquis AD, Jezek F, Pinsky D, Beard DA. Hypoxic pulmonary vasoconstriction as a regulator of alveolar-capillary oxygen flux: A computational model of ventilation-perfusion matching. PLOS Computational Biology 2021. DOI:10.1371/journal.pcbi.1008861.
177. Matute-Bello G, Downey G, Moore BB et al. An official American Thoracic Society Workshop Report: Features and Measurements of Experimental Acute Lung Injury in Animals. Am J Respir Cell Mol Biol 2011;44:725-738. DOI:10.1165/rcmb.2009-0210ST.
178. Yehya N. Lessons learned in acute respiratory distress syndrome from the animal laboratory. Ann Transl Med 2019;7::503. DOI:10.21037/atm.2019.09.33.
179. Nova Z, Skovierova H, Calkovska A. Alveolar-Capillary Membrane-Related Pulmonary Cells as a Target in Endotoxin-Induced Acute Lung Injury. Int J Mol Sci 2019;20:831. DOI:10.3390/ijms20040831.
180. Stenlo M, Hyllen S, Silva IAN. Increased particle flow from airways precedes clinical signs of ARDS in a porcine model of LPS-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2020;318:L510-L517. DOI:10.1152/ajplung.00524.2019.
181. Millar JE, Wildi K, Bartikowski N et al. Characterizing preclinical sub-phenotypic models of acute respiratory distress syndrome: an experimental ovine study. Physiological Reports 2021;9:e15048. DOI:10.14814/phy2.15048.
182. Ramadori G, Sipe JD, Colten HR. Expression and regulation of the murine serum Amyloid A (SAA) Gene in extrahepatic sites. J Immunol 1985.135:3645-3647.
183. D'Agostino F, Walters KA, Xiao Y et al. Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19. Sci. Transl. Med. 2021;13:eabj7790.
DOI:10.1126/scitranslmed.abj7790.
184. Neubauer K, Ritzel A, Saile B, Ramadori G. Immunology Lett 2000;74:153-164. DOI: 10.1016/S0165-2478(00)00203-0

185. Davis HA Pathology of Dehydration Shock. Archives of Surgery 1941;42(5):939-955. DOI:10.100/archsurg.1941.01210110141012.
186. Creel-Bulos C, Hockstein M, Amin N et al. Acute Cor Pulmonale in Critically Ill Patients with Covid-19. N Engl J Med. 2020. DOI:10.1056/NEJMc2010459.
187. Watkins JC, Torous VF, Roberts DJ. Defining Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Placentitis. Arch Pathol Lab Med 2021;145:1341-1349. DOI:10.5858/arpa.2021-0246-SA).
188. Gluecker T, Capasso P, Schnyder P et al. Clinical and Radiologic Features of Pulmonary Edema. RadioGraphics 1999;19:1507-1531.
189. Warren M, Zhao Z, Koyama T et al. Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes in ARDS. Thorax 2018;73:840-846. DOI:10.1136/thoraxjnl-2017-211280.
190. Zimatore C, Pisani L, Lippolis V et al. Accuracy of radiographic assessment of lung edema score for the diagnosis of ARDS. Front Physiol 2021;12:672823. DOI:10.3389/fphys.2021.672823.
191. Knaus WA, Wagner DP, Draper EA et al. The APACHE III Prognostic System. Risk Prediction of Hospital Mortality for Critically Ill Hospitalized Adults. CHEST 1991;100:1619-1636.
192. Rahaghi FN, Ross J, Gonzalez G, Agarwal MA. Pulmonary vascular morphology as an imaging biomarker in chronic thromboembolic pulmonary hypertension. Pulmonary Circulation 2016;6:70-81. DOI:10.1066/685081
193. Rahaghi FN, Argemi G, Nardelli P et al. Pulmonary vascular density: comparison of findings on computed tomography imaging with histology. Eur Respir J. 2019;54:1900370. DOI:10.1183/13993003.00370-2019.
194. Synn A, Bayanova KL, Li W et al. Ambient air Pollution exposure and radiographic pulmonary vascular volumes. Environmental Epidemiology 2021;5:e143. DOI:10.1097/EE9.0000000000143.
195. Walsh CL, Tafforeau P, Wagner WL et al. Imaging intact human organs with local resolution of cellular structures using hierarchical phase-contrast tomography. Nature Methods 2021;18:1531-1541. DOI:10.1038/s41592-021-01317-x.
196. Eckermann M, Frohn J, Reichardt M et al. 3D virtual pathohistology of lung tissue from COVID-19 patients based on phase contrast X-ray tomography. eLife 2020;9:e60408. DOI:10.7554/eLife.60408.
197. Menter T, Halsbauer JD, Nienhold R et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology 2020;77:198-209. DOI:10.1111/his.14134.
198. Yuan S, Jiang S-C, Zhang Z-W et al. The Role of Alveolar Edema in COVID-19. Cells 2021;10:1897. DOI:10.3390/cells10081897.

- 199.Liu N,He G,Yang X et al. Dynamic changes of Chest CT follow-up in Coronavirus Disease-19 (COVID-19) pneumonia:relationship to clinical typing.BMC Medical Imaging 2020;20:92.DOI10.1186/s12880-020-00491-2.
- 200.Huang Y,Li Z,Guo H et al.Dynamic Changes in Chest CT findings of patients with coronavirus disease 2019 (COVID-19) in different disease stages:a multicenter study.Ann Palliat Med 2021;10:572-583.DOI:10.21037/apm-20-2484.
201. Polak SB, Van GOOL IC, Cohen D et al.A systematic review of pathological findings in COVID-19:a pathophysiological timeline and possible mechanisms of disease progression. Modern Pathology 2020 June 22. DOI: 10.1038/s41379-020-0603-3
- 202.Santoriello D,Khairallah P,Bomback AS et al.Postmortem kidney pathology findings in patient with COVID-19.JASN 2020;31:2158-2167. DOI: 10.1681/ASN.2020050744
- 203.Mohanty SK,Satapathy A,Naidu MM et al.Severe acute respiratory syndrome coronavirus-2(SARS-CoV-2) and coronavirus disease 19 (COVID-19)-anatomic pathology perspective on current knowledge.Diagnostic Pathology 2020;15:103. DOI: 10.1186/s13000-020-01017-8
- 204.Dolhnikoff M,Duarte-Neto AN,Saldiva PHN,Caldini E.Using EM data to understand COVID-19 pathophysiology.Lancet2021;397:196-197. • DOI: 10.1016/S0140-6736(21)00034-9
- 205.Mohanty SK,Satapathy A,Naidu MM et al.Severe acute respiratory syndrome coronavirus-2(SARS-CoV-2) and coronavirus disease 19 (COVID-19)-anatomic pathology perspective on current knowledge.Diagnostic Pathology 2020;15:103. DOI: 10.1186/s13000-020-01017-8
- 206.Dolhnikoff M,Duarte-Neto AN,Saldiva PHN,Caldini E.Using EM data to understand COVID-19 pathophysiology.Lancet2021;397:196-197. • DOI: 10.1016/S0140-6736(21)00034-9
- 207.Lee M-H,Perl DP, Nair G,Li WL et al.Microvascular injury in the brains of patients with Covid-19.New Engl J Med 2020 Dec 30. DOI: 10.1056/NEJMc2033369
- 208.Maccio U;Zinkernagel As,Shambat SM et al.SARS-CoV2 leads to a small vessel endothelitis in the heart.EBiomedicine 2021;63:103182. DOI: 10.1016/j.ebiom.2020.103182
- 209.Gonzalez-Lopez JJ, Espinar B-F,Ye-Zhu C.Symptomatic Retinal Microangiopathy in a patient with Coronavirus Disease 2019(COVID-19):Single Case Report.OCULAR IMMUNOLOGY AND INFLAMMATION. DOI: 10.1080/09273948.2020.1852260
210. El Jamal SM,Pujadas E Ramos I et al.Tissue-based SARS-CoV-2 detection in fatal COVID-19 infections:Sustained direct viral-induced damage is not necessary to drive disease progression.Human Pathology2021;114:110-119.doi:10.1016/j.humanpath.2021.04.012.
- 211.Pannone G,Caponio VCA, De Stefano IS et al.Lung histopathological findings in COVID-19 disease-a systematic review.Infectious Agents and Cancer.2021;16:34.DOI:10.1186/s13027-021-00369-0.

212. Batan SS, Fabro AT. Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. *Respiratory Medicine* 2021;176:106239. DOI:10.1016/j.med.2020.106239.
213. Mansueto G. COVID-19: Brief Check through the pathologist's Eye (autopsy archive). *Pathology Research and Practice* 2020;216:153195. DOI: 10.1016/j.prp.2020.153195
214. Sessa F, Salerno M, Pomara C. Autopsy Tool in Unknown Diseases: The Experience with Coronaviruses (SARS-CoV, MERS-CoV, SARS-CoV-2). *Medicina* 2021;73:309. DOI:10.3390/medicina73040309.
215. Armstrong D. The COVID-19 pandemic and cause of death. *Social Health and Illness* 2021;43:1614-1626. DOI:10.1111/1467-9566.13347.
216. Chilvers MA, McKean M, Rutman A et al. The effects of coronavirus on human nasal ciliated respiratory epithelium. *Eur Respir J*. 2001;18:965-970. DOI:10.1183/09031936.01.00093001.
217. Ahn JH, Kim JM, Hong SP et al. Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19. *J Clin Invest* 2021;131:e148517. DOI:10.1172/JCI14517.
218. Gallo O, Locatello LG, Mazzoni A. The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. *Mucosal Immunology* 2021;14:305-316. DOI:10.1038/s41385-020-00359-2.
219. Kahn M, Yoo SJ, Clijsters M et al. Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. *Cell* 2021;184:5932-5949. DOI:10.1016/j.cell.2021.10.027.
220. Smith N, Goncalves P, Charbit B et al. Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. *Nature Immunology* 2021;22:1428-1439. DOI:10.1038/s41590-021-01028-7.
221. Meinhardt J, Radke J, Dittmayer C et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. *Nature Neuroscience* 2021;24:168-175. DOI:10.1038/s41593-020-00758-5.
222. Age-related differences in the nasal mucosal immune response to SARS-CoV-2. *Am J Respir Cell Mol Biol* 2022;66:206-222. DOI:10.1165/rcmb.2021-0292OC.
223. Hooper JE, Padera RF, Dolhnikoff M et al. A Postmortem Portrait of the Coronavirus Disease 2019 (COVID-19) Pandemic. A Large Multi-institutional Autopsy Survey Study. *Arch Pathol Lab Med* 2021;145:529-535. DOI:10.5858/apa.2020-0786-SA.
224. Picetti D, Foster S, Prangle AK et al. Hydration health literacy in the elderly. *Nutrition and Health* 2017;4:227-237. DOI: 10.3233/NHA-170026

225. Myyake Y. Pathophysiology of Heat Illness: Thermoregulation, risk factors, and indicators of aggravation. *JMAJ* 2013;56:167-173.
226. Rowat A, Graham C, Dennis M. Dehydration in hospital-admitted stroke patients. *Stroke*. 2012;43(3):857-859 DOI: 10.1161/STROKEAHA.111.640821
227. Armstrong LE, Kavouras S. Thirst and Drinking Paradigms: Evolution from single factor effects to Brainwide Dynamic Network: *NUtrients* 2019;11: 2864. DOI: 10.3390/nu11122864
228. Vassiliou AG, Kotanidou A, Dimopoulou I, Orfanos SE. Endothelial damage in acute respiratory distress syndrome. *Int J Med sci*. 2020;21:8793. DOI: 10.3390/ijms21228793
229. Geier MR, Geier DA. Respiratory conditions in coronavirus disease 2019 (COVID-19): important considerations regarding novel treatment strategies to reduce mortality. *Medical Hypothesis* 2020;140:109760. DOI: 10.1016/j.mehy.2020.109760
230. Menezes RG, Rizwan T, Saad Ali et al. Postmortem findings in COVID-19 fatalities: A systematic review of current evidence. *Legal Medicine* 2021. DOI:10.1016/j.legalmed.2021.102001.
231. Wenqi Z, Yingquan Z, Mi C et al. A death of Malignant Hyperthermia Performed Autopsy: A Case Report. *Am J Biomed Sci Res*. 2020;10. DOI:10.34297/AJBSR.2020.10.001525.